Entities

Eva Tay is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is Singapore.

Fredrik Backman is a Managing Director at EQT, where he leads client relations and capital raising across the Nordic region as part of the Global Client Solutions team. Based in Stockholm, Fredrik covers Nordic institutional investors and draws on more than 15 years of international equity market experience spanning Moscow, New York, London, and Stockholm. Fredrik joined EQT in January 2019. Prior to EQT, he worked at Citi, where he focused on developing the firm's Nordic institutional equity offering. Fredrik holds an M.Sc. in Business Administration and Economics with a major in Finance from Stockholm University, Stockholm Business School.

Partner, Global Co-Head of Capital Markets Georg is Global Co-Head of Capital Markets. He is responsible for overseeing the debt and equity capital markets activities across EQT's business lines. Georg joined EQT Partners in November 2008. Prior to joining EQT Partners, Georg worked at Credit Suisse within Leverage Finance Origination and M&A in London and Frankfurt. Prior, he was a member of the acquisition financing team at Dresdner Kleinwort.Georg holds a master degree in business administration from the European Business School (ebs) Oestrich Winkel.

Ines Leung is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is San Francisco.

Isabella Richards is publicly listed by EQT as Associate within Infrastructure / Infrastructure APAC. The published office is Sydney.

Jaakko Kaltio is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Jacki Speaker, Managing Director, Private Capital Jacki Speaker joined EQT Partners in May 2026. She leads Private Capital fundraising activities across the Eastern United States and works with the firm’s Consultant Relationships. Prior to joining EQT, Jacki spent four years at Blackstone, where she focused on raising capital for Blackstone’s private equity strategies. Prior to that, she spent over eight years on KKR’s Client & Partner Group, where she focused on capital raising across the firm’s investment capabilities. She began her career at Credit Suisse Asset Management. Jacki holds a B.B.A. from the Goizueta Business School of Emory University.

Jacob Alayof is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Jacob Alvarado is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Jacob Zhu （朱泓静） is publicly listed by EQT as Associate within Infrastructure / Infrastructure APAC. The published office is Sydney.

James Ash is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

James Lax is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is Stockholm.

Jason Cheon （천호성） is publicly listed by EQT as Associate within Infrastructure / Infrastructure APAC. The published office is Seoul.

Jay Chae is a Managing Director in EQT's Global Client Solutions team, responsible for institutional investor coverage across Korea and Southeast Asia. He joined EQT in 2018. Prior to EQT, Jay spent a decade in M&A across principal and advisory roles in Hong Kong, having worked at Heemin Capital, Comprador Limited, Blackstone, and Lehman Brothers. Jay holds a Bachelor of Business Administration from Korea University.

Jeff Clarke is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is New York.

Jin Zou is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is Hong Kong.

Jinesh Bothra is publicly listed by EQT as Analyst within Infrastructure / Infrastructure Europe. The published office is Bengaluru.

Joe Tremblay is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is Los Angeles.

Johan Hylander joined EQT in September 2015. He is part of the EQT Infrastructure team, where he is responsible for all capital markets activities across EQT Infrastructure’s US portfolio. Prior to joining the EQT Infrastructure team in October 2020, Johan was an investment professional in the EQT Credit Opportunities fund. Before joining EQT, he worked in leveraged finance at Citigroup in London, focusing on the evaluation, execution, and monitoring of leveraged buyouts and leveraged corporates across EMEA. Johan holds a Master’s degree in Economics and Business Administration from Copenhagen Business School.

Johann Moon is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / GCS & CM Specialist Functions. The published office is London.

Jonas Ahlgren is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is Stockholm.

Jordan Esrig is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Josefin Öhman joined EQT Partners in November 2019 in the Global Client Solutions team. Previously, Josefin was at Carnegie Investment Bank M&A in Helsinki and at Capstone Partners placement agent in Singapore. Josefin holds an MBA from INSEAD and a M.Sc. in Economics from Hanken School of Economics in Helsinki (Finance, Economics).

Joseph Fuda is a Partner in the Client Relations and Capital Raising team. Joseph worked for BPEA from 2019 until 2022, when the company joined forces with EQT. Prior to joining BPEA, Joseph was a Principal with TPG Capital based in New York and San Francisco. Mr. Fuda held prior roles at CBRE Caledon and CIBC in Toronto. Joseph holds a Bachelor of Arts (BA) in International Relations from the University of Western Ontario and an Honor’s in Business Administration (HBA) from the Richard Ivey School of Business (Western).

Kopal Gupta is publicly listed by EQT as Analyst within Infrastructure / Infrastructure Europe. The published office is Bengaluru.

Lauren Fong is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Lukasz Roginski is publicly listed by EQT as Associate, Performance and Business Control (individual profile: Associate) within Infrastructure / Infrastructure Specialist Functions. The published office is Warsaw.

Luna Li is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Magnus is a Partner and Global Head of Equity Capital Markets at EQT, where he leads the firm's approach to public markets transactions. He also serves as Head of EQT Norway. Magnus joined EQT Partners in 2016. He previously led EQT's Global Industrial Tech Sector Team. Magnus holds an MSc in Finance from the Norwegian School of Management. Prior to joining EQT, he spent twelve years in the Corporate Finance department of ABG Sundal Collier in Oslo, most recently as Co-Head of Investment Banking and Head of Equity Capital Markets.

Manjul Ramchandani is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is New York.

Marcelo Zavala Rangel is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Maria Lamprecht is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Martin Donnelly is publicly listed by EQT as Partner within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is Sydney.

Mary Lynn Eubanks is publicly listed by EQT as Co-Head of Product (Real Assets) within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is New York.

Melissa Chang is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is Hong Kong.

Michelle Jang is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Mikael Moll joined EQT Partners in Stockholm in 2018. Prior to joining EQT Partners, Mikael was a Partner at Zeres Capital. Previously he worked as an Investment Director at CapMan and at the Investment Banking division of Merrill Lynch in London. Mikael Moll holds a M.Sc. in Economics and Business Administration from Stockholm School of Economics.

Monica joined EQT's Capital Markets team in June 2021. Prior to joining the firm, she worked in Credit Suisse's Financial Sponsors Group in London. She transferred from Credit Suisse's Sydney office, in which she worked across Structured Products and Off-Shore Leveraged Finance, having joined the firm in 2015. She began her finance career at HSBC in Sydney as a graduate in 2013, where she worked with the bank's Debt Capital Markets and Loan Syndications teams. Monica holds a Bachelor of Laws and a Bachelor of Arts in Communication (Journalism) from the University of Technology, Sydney.

Morris Boger is publicly listed by EQT as Analyst within Infrastructure / Infrastructure Europe. The published office is Munich.

Nick Thorn is publicly listed by EQT as Co-Head of Product (Private Capital) within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is Hong Kong.

Nick Tsavliris is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is London.

Olivia Vallgårda is publicly listed by EQT as HR Associate within Infrastructure / Infrastructure Specialist Functions. The published office is Stockholm.

Paola Maleh is a Partner based in EQT's London office and is Global Head of Institutional Clients for all EQT products excluding RE. Prior to joining EQT in 2015, Paola was Head of EMEA Marketing and Investor Relations at Silver Lake in London. Previously, she was with Abu Dhabi Investment Authority (“ADIA”) where she focused on private equity fund investments and co-investments as well as on developing the Private Equity department’s investment strategy. Before ADIA, Paola was with McKinsey & Company based in the New York and London offices. Paola also worked at Goldman Sachs and EMC² in Boston as a software engineer. Paola received an M.B.A. from the MIT Sloan School of Management, and a B.Sc. in Computer Science from McGill University.

Peter Grancaric joined EQT in March 2025. Based in the London office, he focuses on Infrastructure & Energy Transition strategies and is responsible for investor coverage across the Nordics, UK & Ireland, Benelux, and Israel. Peter brings over 25 years of capital markets experience across the European region. Prior to joining EQT, he was a Managing Director in the Client Relations team at Brookfield Asset Management. He holds an MSc in Finance & Investments from Bayes Business School and completed the Executive Education Programme in Corporate Finance at the London Business School.

Rene Hoepfner joined EQT in October 2024. Based in Munich, Rene has over 20 years of private markets experience across multiple disciplines including investing, investment consulting and investor relations. Prior to joining EQT, Rene was the Head of Investor Relations, Europe at LaSalle and a member of the firm’s European Management Board. He also advised institutional investors on their private markets investments in particular private equity, private debt, infrastructure and real estate at Mercer and Feri for almost 10 years, and worked for various alternative investment managers. Rene has a degree in finance and economics from Humboldt-University of Berlin.

Rhiannon Nind is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Rishabh Chugh is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is London.

Rob Ryan is publicly listed by EQT as Global Head of Market Risk Advisory within Global Client Solutions & Capital Markets / Capital Markets. The published office is Singapore.

Rohan Khanolkar is a Managing Director – Debt Capital Markets at EQT, where he leads debt capital markets activities for the firm across the Asia-Pacific region as part of the Private Capital Asia team. Based in Hong Kong, Rohan's work spans the APAC region, supporting EQT's Private Capital investment activities across debt financing and loan syndications. Rohan joined EQT in 2017. Prior to joining EQT, he was part of the Leveraged Finance and Loan Syndications team at Bank of America in Hong Kong, and earlier held a role in the firm's Credit Risk team in India. Rohan holds a Bachelor of Engineering and an MBA in Finance from the University of Mumbai. He is also a CFA and FRM charterholder.

Sabrina Tatarskaya is publicly listed by EQT as HR Associate within Infrastructure / Infrastructure Specialist Functions. The published office is New York.

Sam Breakwell is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is London.

Savina Eneva is publicly listed by EQT as Managing Director - Global Client Solutions within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is London.

Sean Farrell is publicly listed by EQT as Head of GCS & CM HR within Global Client Solutions & Capital Markets / GCS & CM Specialist Functions. The published office is London.

Sean Ham is a Partner and Head of Asia Pacific within Global Client Solutions at EQT Partners. He joined EQT Partners in January 2016. Prior to joining EQT Partners, Sean worked at Blackstone in Hong Kong, where he focused on investors coverage and business development. Before Blackstone, Sean was with investment banks in private funds placement including UBS and Merrill Lynch. He was also with Cornerstone Equity Partners and VIG Partners in leveraged buyout and growth capital investments. Sean holds an MBA from Columbia Business School and studied an MSc in Business Administration at Seoul National University.

Sewoong Park is publicly listed by EQT as Associate within Infrastructure / Infrastructure APAC. The published office is Tokyo.

Simone Pugliese is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is London.

Teia Merring is publicly listed by EQT as Partner, Global Head of Strategic Partnerships within Global Client Solutions & Capital Markets / Global Client Solutions. The published office is London.

Teresa Gómez De Olea is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is Madrid.

Thomas Redman is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is London.

Tom Addison is publicly listed by EQT as Partner, COO Global Client Solutions within Global Client Solutions & Capital Markets / GCS & CM Specialist Functions. The published office is Victoria.

Tom Nylander is publicly listed by EQT as Associate, Performance and Business Control within Infrastructure / Infrastructure Specialist Functions. The published office is Stockholm.

Tristan Thurlow is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is London.

Vera Rebanova is a Partner at EQT and Global Head of Principal & Family Office Solutions. Based in Zurich, Vera works with families and their investment offices globally, creating strategic alignment across the EQT platform — spanning not only funds but also direct investment opportunities across the full spectrum of EQT's strategies. Vera is a member of the EQT Global Client Solutions Management Group. She holds a Master of Science in Political Economy from the London School of Economics and a Bachelor of Arts in International Relations from Richmond University in London.

Herbert Gurney is publicly listed by EQT as Associate within Infrastructure / Infrastructure US. The published office is New York.

Himanshu Gopal is publicly listed by EQT as Associate within Infrastructure / Infrastructure APAC. The published office is Hong Kong.

Ignacio Manrique is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is Madrid.

Ilka Holtgreve is publicly listed by EQT as Associate within Infrastructure / Infrastructure Europe. The published office is Munich.

Alec Ross is a published Board Partner of Collective Global’s Amplo platform. An author and technology-policy specialist, his career includes an innovation-adviser position at the US State Department during the Obama administration and academic work at the University of Bologna, Johns Hopkins and Columbia. His current manager-directory affiliation is an advisory role.

John Key is a published Board Partner affiliated with Collective Global’s Amplo platform. He was New Zealand’s prime minister from2008 through2016 and previously worked in investment banking, including foreign-exchange and derivatives leadership at Merrill Lynch. The advisory designation is not assumed to be full-time employment or a statutory manager directorship.

TCD Capital is a Brussels-based venture capital and private equity manager investing in European growth companies across Technology, Life Sciences and Smart Living. Its legal manager is active Belgian company TheClubDeal Capital Advisors SA, enterprise BE0647.570.713, incorporated January 28, 2016. The firm announced its change of public brand from TheClubDeal to TCD Capital on February 19, 2024; this does not change the legal manager. Its own portfolio includes brain clinical-trial analytics, neurostimulation, blood-brain-barrier therapeutics, surgical planning and AI-enabled restaurant supply management. Fund I and Fund II are separate investment vehicles; the manager also arranges club deals and advisory mandates. Fund II completed its final close at approximately EUR40 million at the end of June 2023. Separate co-investments, company financing rounds and aggregate structured transactions are not added to fund capital. Current public affiliations distinguish executive staff, non-executive partners, specialist advisers and Fund II board members. Two named interns have initials rather than genuine public headshots. Institutional investment attribution is preserved separately from individual club-deal investors, with no guessed fund allocation or personal check.

Henrik Nordlander is a Partner at Collective Global. His previous career included leading alternative investments at Swedish pension fund AP3 and emerging-market investing at Swedfund International. He holds degrees from Stockholm School of Economics and Lund University. Assets overseen in those historical positions are not a Collective fund size.

Sam Garcia is a Partner in Collective Global’s Amplo platform, focused on seed and SeriesA investments. His primary biography lists board affiliations across enterprise software and financial technology companies and a teaching appointment at Harvard Law School. He studied business at the University of Texas at Austin and law at Harvard. Company board service is distinct from personal cash attribution.

Adam Robbins is a Partner at Collective Global. He formerly worked on Capital Constellation at Wafra, with earlier institutional-investor work at the World Economic Forum, World Bank, International Forum of Sovereign Wealth Funds and Amundi. His education includes Colby College and the Fletcher School at Tufts; he also undertakes innovation and sustainability research at Panmure House.

Jennifer Johnson is Collective Global’s Chief of Staff, supporting leadership coordination, team operations and communications. Her previous work supported management and business development at Wafra, with earlier roles assisting executive teams at Mack-Cali Realty and Harris Corporation. Those prior positions are historical; the current primary directory confirms her Collective role.

Ana Leticia Maragno is Jeito Capital’s current Director of Translational science. Former Servier drug-discovery/translational-research project leader. Institut Curie cellular/molecular-biology PhD, São Paulo biochemistry masters and UNESP pharmacy qualification.

Anastasiya Sybirna is Jeito Capital’s current Principal. Former F-Prime healthcare investor, McKinsey engagement manager and Advancy consultant. Cambridge stem-cell-biology doctorate, ENS molecular/cell-biology masters and Lviv biology degree.

Carole Cheung is Principal, Finance at Collective Global, responsible for financial management and reporting. Her prior experience includes Affinius Capital, H/2 Capital Partners and KPMG in Hong Kong and Chicago. She studied at the Hong Kong University of Science and Technology and holds CPA and FCCA qualifications, according to the manager’s biography.

Anand Radhakrishnan is a Partner and Chief Operating and Financial Officer of Collective Global. Earlier he spent more than two decades at Investcorp in technology partnerships, private-equity operations and corporate development, following work at Carlyle and Robertson Stephens. He studied electrical engineering and computer science at MIT and business at Harvard; his MIT work included natural-language-processing research.

John Paul (JP) Schnapper-Casteras is Collective Global’s General Counsel and Chief Compliance Officer. He has advised Amplo on venture transactions since2020 and also counsels technology businesses and nonprofit organizations. His background includes appellate clerkships and Supreme Court briefing. He holds a law degree from Stanford, a public-policy degree from Harvard and earlier Stanford degrees.

Magdalena Jonikas is Jeito Capital’s current Partner. Former Syncona partner/company-builder and McKinsey associate partner. Stanford bioengineering PhD/MS, Penn bioengineering degree and Harvard/Boston Children’s postdoctoral research.

Samit Hirawat is Jeito Capital’s current Operating Partner, Medical Strategy. Former Bristol Myers Squibb chief medical officer/global drug-development leader and Novartis oncology-development executive. Sawai Man Singh medical degree and North Shore internal-medicine/oncology training.

Sarah Shackelton is Jeito Capital’s current Partner, Talent. Former Oxford Science Enterprises talent chief and Abingworth talent/marketing partner, with earlier executive-search and US trade-negotiation work. Princeton economics/political-science MPA and Pomona international-relations degree.

Sheel Tyle is Collective Global’s co-founder and co-CEO, with responsibilities spanning early-stage companies, venture growth and ownership stakes in venture managers. The primary biography identifies his involvement in AI, mental-health and software investing. He studied at Stanford and Harvard Law School and is a Texas-bar member. The manager also describes his professional sports ownership and education and health philanthropy.

Sarah Oliver Ricome is Jeito Capital’s current Executive Assistant. Current named executive assistant with an authentic own portrait. Detailed career and education biography is not published in the current directory.

Collective Global is a venture investment and asset-management platform led by co-founders and co-CEOs Daniel de Faro Adamson and Sheel Tyle. Its legal adviser is Collective Global Management, L.P., an active exempt reporting adviser identified by SEC/CRD328741 and file802-129181 in its March30,2026 Form ADV. Its strategies combine venture-manager ownership stakes (Elevate), early-stage investing through the Amplo platform and opportunistic venture investments (Tactica). The platform was publicly launched in November2023 with institutional asset-owner participation. Its reported assets under management are not a closed fund size. The current primary directory publishes nine team members and six Board Partners; Board Partners are separately qualified affiliations, including Amplo-platform advisers, rather than assumed full-time employees or statutory directors. Direct investments include artificial intelligence, scientific discovery, enterprise technology and other areas. Lila Sciences named Collective Global as a co-lead of the actual USD235million first closing of its SeriesA on September15,2025. Current manager-level evidence distinguishes the Amplo platform from the retained historical Amplo organization record; no legal identity or historical buyer links are merged. The SEC filing identifies exact managed Amplo and Collective fund vehicles. Regulatory gross asset values, minimum commitments, an indefinite offering and potential future investment commitments are distinguished from actual subscriptions and final closed fund capital. Source-qualified original subscriptions can be recorded where a FormD reports securities sold; unknown final close dates and amounts remain undisclosed.

Olga Golushko is Jeito Capital’s current Executive Assistant. Earlier family-office communications and events-agency work; Paris XII comparative-literature PhD and Novosibirsk literature masters, with intercultural-literature/tourism-marketing education.

Jessica Fadel is Jeito Capital’s current Executive Assistant of Founder and CEO. Earlier executive-assistant work supporting EY France sustainability partners and Cathay Capital managing partners; began her career in London.

Ivana Trivunovic is Jeito Capital’s current Analyst. Earlier Kurma Biofund analyst and biotechnology scientific adviser; Bordeaux neurobiology PhD with Oxford venture-capital/entrepreneurship training.

Boris Kere is Jeito Capital’s current Compliance Officer. Previously compliance consultant at AGAMA Conseil and investment-funds legal professional at Dentons Luxembourg; Nancy/University of Lorraine business-law/tax and international-business-law masters.

Henri Mazeau is Jeito Capital’s current Legal Counsel. Paris-bar lawyer with prior Weil, Gotshal & Manges private-equity transaction practice; Panthéon-Assas business-law/tax and ESCP management education.

Hortense de Meaux is Jeito Capital’s current Finance Manager, Fund. Former KPMG HealthTech financial auditor; Neoma audit/accounting masters. Supports fund administration and portfolio finance monitoring.

Chloé Roche is Jeito Capital’s current Analyst. Earlier healthcare investing at AurigaPartners and DNAFinance, plus Bpifrance/HelloTomorrow work. AgroParisTech engineering and Sciences Po finance/strategy education.

Noémie Timsit is Jeito Capital’s current Associate. Former Jeito junior-analyst intern with prior business-development experience at an AI diagnostics startup addressing neurodegenerative disorders. ESCP management masters and NYU biology/biotech-strategy study.

Benjamin Caillier is Jeito Capital’s current Finance Director, Jeito Capital. Joined 2023 after senior finance work for holding/investment companies and family offices in France and Luxembourg; ESCE finance/strategy masters.

Manon Frachon is Jeito Capital’s current Project Manager. Earlier healthcare M&A and financing work at investment banks, plus management-control and internal-audit experience; Audencia management/corporate-finance masters.

Estelle Ruotte is Jeito Capital’s current Finance Manager, Fund. Former EY healthcare financial auditor, with fund and portfolio financial-monitoring responsibilities; Paris Dauphine accounting/control/audit masters.

Daniel Wolle is Jeito Capital’s current Principal. Former JPMorgan biotechnology equity-research analyst and Piper Jaffray analyst. Princeton molecular-biology PhD and UCLA biochemistry degree.

Charlotte Formont is Jeito Capital’s current Head of Legal. Joined 2022 after Weil, Gotshal & Manges private-equity legal practice 2017–2022. Paris-bar lawyer with London School of Economics corporate-law LLM and Sciences Po economic-law education.

Alain Rougon is Jeito Capital’s current Finance Advisor (external provider, Prodensia). External adviser through Prodensia, the outsourced fund-finance firm he founded 2015. Supported Jeito as interim CFO fromJanuary 2020, following fund CFO/secretary-general and audit work.

Chloé Morlaàs is Jeito Capital’s current Investor Relations Director. Former healthcare consultant and HealthTech-association professional; ESSEC management and London School of Economics science MPhil.

Evaldo Bifulco Jr. is Jeito Capital’s current Head of Sustainability, Compliance & Risk (RCCI). Former ODDO BHF private-equity compliance head, EY risk consultant and Société Générale compliance officer; Panthéon-Sorbonne finance and banking-risk/compliance masters.

Maya Chkaiban is Jeito Capital’s current Principal. Joined 2020 and promoted PrincipalOctober 2025. Paris Descartes pharmacy/chemistry education and ESSEC management degree; earlier biotechnology operations and healthcare NGO work.

Pascal Touchon is Jeito Capital’s current Partner. Atara CEO2019–2024 and former Novartis cell/gene-therapy leader. Toulouse veterinary doctorate, IAE management qualification and INSEAD MBA; published biotech board experience.

Claudio Costa-Neto is Jeito Capital’s current Partner & Chief Scientific Officer. Former São Paulo medical-school biochemistry professor and department head. Holds molecular-biology/pharmacology doctorate based on São Paulo/Copenhagen research and structural-biochemistry habilitation; scientific and translational-research background.

Karin van Baelen is Jeito Capital’s current Chief Regulatory Advisor. Former global regulatory-affairs leader at Janssen/Johnson & Johnson, with experience across international, regional and operational regulatory functions.

Annette Clancy is Jeito Capital’s current Operating Partner, M&A & Strategy. Jeito founding-team member and former GSK worldwide transactions/alliance-management leader. Previously chaired SOBI; holds Bath pharmacology BSc and brings biotechnology board and M&A experience.

Ksenija Pavletic is Jeito Capital’s current General Partner & Chief Commercial Officer. Former PregLem CEO and Serono commercial executive. Holds Zagreb biotechnology masters and American Graduate School of Business MBA.

Sabine Dandiguian is Jeito Capital’s current Managing Partner. Former Johnson & Johnson and Janssen executive with European medical-business leadership and market-access experience; graduated in finance from ESCP.

Rafaèle Tordjman is Jeito Capital’s current Founder & CEO. Physician-scientist trained in hematology and immunology, formerly a Sofinnova Partners investor from 2001 to 2017. Founded Jeito in 2018 and the WITH healthcare association in 2010; completed INSEAD management training.

Daniel de Faro Adamson is publicly identified by Lila as Board Member. Co-founder and CEO of Collective Global, whose own public directory also uses Daniel Adamson. Lila publishes him as a board member; institutional investment is kept separate from any unproven personal check.

EQT is a global private-markets investment organization whose publicly listed parent is EQT AB in Stockholm. The group and its distinct managers and advisers invest across Private Capital, Infrastructure, Real Estate and Secondaries, from early-stage technology and life-sciences businesses to mature companies and essential infrastructure. Its active ownership approach supports growth, operational improvement, digitalization, artificial intelligence and sustainability through sector teams and industrial advisers. Technology, healthcare and AI infrastructure are major investment themes; its Scaleup Europe mandate backs European strategic technology companies at growth and late stages. EQT Ventures, EQT Life Sciences and the independent EQT Foundation have distinct strategies and identities within or alongside this broader platform.

Published member of EQT’s group Executive Committee. Chief People Officer.

Published member of EQT’s group Executive Committee. Co-Head of Private Capital EU & NA.

Published member of the EQT AB Board of Directors. Board member.

Published EQT group/strategy affiliation: Partner; Head of EQT Ventures and Head of Growth US. This identifies an affiliation within EQT’s platform and does not assert undisclosed legal employment by EQT AB.

Published EQT group/strategy affiliation: Institutional Partner; Chair of Scaleup Europe Fund Investment Committee. This identifies an affiliation within EQT’s platform and does not assert undisclosed legal employment by EQT AB.

Published member of EQT’s group Executive Committee. Chief Operating Officer.

Published EQT group/strategy affiliation: Partner; global co-lead of AI Infrastructure strategy. This identifies an affiliation within EQT’s platform and does not assert undisclosed legal employment by EQT AB. Own biography also gives his full name as Johann-Christoph Balzer and says he joined EQT Partners in October 2013.

Published EQT group/strategy affiliation: Honorary Chairperson and Founder. This identifies an affiliation within EQT’s platform and does not assert undisclosed legal employment by EQT AB.

Published member of the EQT AB Board of Directors. Board member.

Published member of the EQT AB Board of Directors. Board member.

Published member of EQT’s group Executive Committee. Chief Financial Officer.

Published member of EQT’s group Executive Committee. Global Head of Real Estate.

Published member of the EQT AB Board of Directors. Board member.

Published member of EQT’s group Executive Committee. Partner, Head of Global Client Solutions. Distinct from the James Yu affiliated with Qualified Health; EQT biography identifies former Morgan Stanley and JP Morgan banking experience and an EQT Partners appointment in April 2013.

Published EQT group/strategy affiliation: Partner; Head of AI Infrastructure and Transition Infrastructure strategies. This identifies an affiliation within EQT’s platform and does not assert undisclosed legal employment by EQT AB.

Published member of the EQT AB Board of Directors. Chair, EQT Group.

Published member of the EQT AB Board of Directors. Board member.

Published member of EQT’s group Executive Committee. Head and Chief Investment Officer of Coller EQT.

Published member of the EQT AB Board of Directors. Deputy Chairperson.

Published member of the EQT AB Board of Directors. Board member.

Published member of EQT’s group Executive Committee. Partner, Head of EQT Infrastructure.

Published member of EQT’s group Executive Committee. CEO and Managing Partner.

Published member of the EQT AB Board of Directors. Board member.

Published EQT group/strategy affiliation: Partner, Co-Head of Scaleup Europe Fund. This identifies an affiliation within EQT’s platform and does not assert undisclosed legal employment by EQT AB.

Published EQT group/strategy affiliation: Partner, Head of Early Stage Technology. This identifies an affiliation within EQT’s platform and does not assert undisclosed legal employment by EQT AB.

Kenneth Stanley is publicly identified by Lila as SVP, Open-endedness. Developed NEAT and novelty-search methods in artificial intelligence. Previously led open-endedness research at OpenAI and worked at Geometric Intelligence/Uber AI and as a UCF professor; holds UT Austin and Penn computer-science degrees.

Alex Sneider is publicly identified by Lila as Vice President, Head of LILA Origins. Alexandra Sneider, published as Alex, co-founded Lila and previously was a Flagship principal. Holds a Johns Hopkins chemical/biomolecular-engineering doctorate, Harvard anthropology and UMass Lowell chemical-engineering degrees.

Will Smith is publicly identified by Lila as Vice President, Business Development. Previously a McChrystal Group partner and US Army officer. Holds a Wharton MBA and Georgetown degree; this business-development executive is distinct from the actor.

Maddie Silverman is publicly identified by Lila as Vice President, Corporate Development. Madeline Silverman, published as Maddie, previously worked in the Merrill leadership office and at McChrystal Group. Holds a Columbia MBA and Harvard government degree.

Joshua Roth is publicly identified by Lila as Chief Software & Systems Officer. Previously CTO at Ring and a vice president at Amazon. Holds a UCLA computer-science engineering degree and works on integrated hardware, cloud and edge systems. Distinct from the Nimbus patent-law executive of the same name.

Chris O'Donnell is publicly identified by Lila as Chief Government Affairs Officer. Previously worked on dual-use investments at Franklin Venture Partners following thirteen years as a Navy SEAL and roles at Leupold and Northstar. Holds Colorado and San Diego State degrees. Distinct from the OAM Quant executive affiliated with Safar Partners.

Peter Ricci is publicly identified by Lila as Vice President, Controller. A certified public accountant who previously served as Indigo’s global controller and worked in public accounting. His own biography also uses Pete Ricci.

Atul Mistry is publicly identified by Lila as Chief Software Architect. Previously chief architect for Symbotic warehouse-robotics software. Holds Boston University software and UMass Dartmouth electrical-engineering degrees.

Daniele Malleo is publicly identified by Lila as Vice President, AI Science Factory Product. Previously led research and development at Cellares and worked at BD, Abbott and Berkeley Lights. Holds Southampton electrical-engineering postgraduate degrees.

Jack Milwid is publicly identified by Lila as Office of the CEO. Previously co-founder and president of Related Sciences and worked at Flagship and Third Rock. Holds Harvard/MIT medical-engineering, MIT and Colorado School of Mines degrees.

Ryan Leung is publicly identified by Lila as Vice President and Head of Life Science Product. Previously worked at Genentech, Foundation Medicine and PathAI. Holds a Tufts biomedical-engineering degree and develops AI-enabled life-science products.

Rachael Lammers is publicly identified by Lila as Vice President, Head of Autonomous Platform Strategy. Previously worked at Fujifilm Diosynth, Resilience, McChrystal Group and US defense and commerce agencies. Holds Georgia Tech international-affairs and Georgia State political-science degrees.

Sue Kwon is publicly identified by Lila as Chief Communications Officer. Previously led communications at General Catalyst and worked as a CBS reporter and at Symantec and Nokia. Holds a Stanford political-science degree.

Ben Kompa is publicly identified by Lila as Vice President, Head of AI Lab Innovation. Co-founded Lila following machine-learning biotechnology work at Flagship. Holds Harvard, Cambridge and UNC degrees spanning computational biology and machine learning.

Raghav Kohli is publicly identified by Lila as Chief Legal Officer & Corporate Secretary. Previously general counsel at Mithril and worked on legal and strategic partnerships at Waymo. Holds Boston College law and Georgia Tech electrical-engineering degrees.

Bruce Kessler is publicly identified by Lila as Vice President & Associate General Counsel. Previously worked on AI and digital legal matters at Thermo Fisher and legal innovation at Nike. Holds a Boston University law degree and Tufts computer-science degrees.

Jon Hennek is publicly identified by Lila as Chief Revenue & Product Officer. Previously founding chief product officer at Osmo and worked on Indigo Carbon. Holds a Northwestern chemistry doctorate and a St. Thomas science degree; undertook Harvard postdoctoral work.

Mary Jacobs is publicly identified by Lila as Vice President, People. Previously worked on talent and recruiting at Flagship Pioneering and Proclinical. Holds a University of Pittsburgh neuroscience degree.

Gaurav Garg is publicly identified by Lila as Vice President, Software. Previously built scientific and enterprise software at Benchling, Workday, Groupon and Cisco. Holds BITS degrees. This engineer is distinct from the Wing Venture Capital founding partner also named Gaurav Garg.

Bob Gantzer is publicly identified by Lila as Vice President, Next Generation Platform. Works on laboratory automation and AI-controlled scientific instruments. Previously led computation and laboratory technology at Aera and automation at Beam; holds Johns Hopkins biotechnology and Illinois molecular/cellular-biology degrees.

Guillaume Defrance de Tersant is publicly identified by Lila as Vice President, Strategic Finance. Previously worked in finance and strategy at Indigo Agriculture. Holds MIT engineering-management and HEC management degrees.

Ludo Van Den Bosch is Augustine Therapeutics’ scientific founder and chairman of its scientific advisory board. The company was spun out of VIB and KU Leuven in2019 from his HDAC6 research in peripheral neuropathies and neurodegeneration. His VIB–KU Leuven academic affiliation and scientific advisory role are distinct from company executive employment. Ludo Van Den Bosch is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Professor in the Department of Neurosciences at KU Leuven; Group leader at the VIB Center for Brain & Disease Research.; Head of the Laboratory of Neurobiology at VIB; Scientific Founder of Augustine Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

She is an accomplished global healthcare leader with over three decades of experience driving value creation across the pharmaceutical, MedTech, biotech, and digital health industries. Pascale has held executive leadership roles in some of the world’s leading healthcare organizations, including serving as Executive Vice President of Global Pharma and Consumer Healthcare at Sanofi, and led the creation of the Consumer Healthcare division. Prior to that, she was President and Chief Executive Officer of GE Healthcare’s Pharmaceutical Diagnostics business, overseeing global operations, product innovation, and commercialization strategies. She began her career at Becton Dickinson Pharmaceutical Systems. Pascale serves on the boards of several publicly-listed healthcare companies, including Revvity, Fresenius Medical Care, and Regulus Therapeutics, as well as private companies such as Evergen, Lumanity, and CellCarta, playing a pivotal role through governance, financial oversight, and executive mentorship. She was also a Board member at Arkuda Therapeutics before the company was acquired by Johnson & Johnson in January 2025. Her contributions to the industry have been widely recognized, being named one of Fortune’s Top 20 Most Powerful Women in EMEA and receiving the prestigious French distinction, Chevalier de la Légion d’Honneur. She is also the author of Tech: The Healthcare Evolution. Witz earned a Master of Business Administration from INSEAD, France, and a Master of Science (MSc) in biochemistry from the Institut National des Sciences Appliquees in Lyon, France. She was also a doctoral student in molecular biology at the CNRS (Centre National de la Recherche Scientifique) in Strasbourg, France.

Patrick Fuller is publicly identified by Lila as Vice President, Product, Physical Sciences. Co-founded Numat while working on doctoral research and developed industrial materials and automation products. Holds Northwestern and Lehigh degrees in engineering and finance.

Tommaso Biancalani is publicly identified by Lila as SVP, Generative Biology. Previously led AI biology work at Genentech and deep-learning genomics at the Broad Institute. Holds a Manchester doctorate and undertook postdoctoral research at MIT.

Amit Aggarwal is publicly identified by Lila as Chief Information Security Officer. Previously spent five years leading IT and security at Moderna and worked at Nokia and HERE. His published background concerns cybersecurity, information systems and scaling scientific organizations.

Dr. Koenig took up his role as CEO of Augustine Therapeutics in January 2025 having served as a Non-Executive Director since May 2022, and as Executive Chairman since June 2024. Gerhard was CEO and Co-founder of Arkuda Therapeutics, a Boston-based biotech company focused on the development of lysosomal function enhancers for the treatment of neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease. Arkuda’s portfolio of lysosomal function enhancers was acquired by Johnson & Johnson, which was announced in January 2025. He is an advisor with Atlas Venture, a Boston-based VC fund, and is Board member on VIGIL Therapeutics. Prior to his current positions, Gerhard served as CEO of Quartet Medicine, CSO and Senior Vice President of FORUM Pharmaceuticals, Vice President of Scientific Programs and Evaluation at Fidelity Biosciences Group (now F' Prime Capital), and held multiple positions at pharmaceutical company Bayer. Gerhard received his PhD and MS degrees in molecular and cellular neurobiology with a minor in biochemistry, graduating summa laude from the University of Heidelberg, Germany. Historical affiliation correction: Augustine’s published biography still names a Vigil board appointment. Vigil Neuroscience’s SEC closing report explicitly records Gerhard Koenig’s board resignation effective August 5, 2025, following Sanofi’s acquisition. His Vigil board appointment is therefore historical, and no current Vigil directorship is asserted.

Andy brings diverse experience in corporate finance, strategy, and business development across the life sciences industry. Before joining Augustine, Dr. Hu was Chief Business Officer of Arkuda Therapeutics, a biotech company focused on neurodegenerative diseases which was acquired by Johnson & Johnson and announced in January 2025. Previously, Dr. Hu was Senior Vice President, Business Development at Dimension Therapeutics, where he was a leader of teams that successfully brought the company through an IPO, several strategic partnering transactions, and ultimately an acquisition by Ultragenyx. Dr. Hu also previously worked as part of the investment banking team at Leerink Partners, where he was part of teams that successfully executed over $600 million in equity financings for public and private life sciences companies, and as a senior consultant at Strategic Decisions Group, where he led strategic consulting engagements for several of the world’s largest biopharma companies. Dr. Hu received his AB in Environmental Science and Public Policy from Harvard University, an M.D. from Baylor College of Medicine, and an MBA from the Jones Graduate School of Management at Rice University. Transaction qualification: Arkuda’s January 9, 2025 issuer announcement describes Johnson & Johnson exercising an option to purchase its portfolio of lysosomal function enhancers. The published career summary’s acquisition wording does not establish acquisition of the entire legal company.

Milad Abolhasani is publicly identified by Lila as SVP, Chemistry. Also an NC State chemical-engineering professor; develops autonomous flow chemistry and self-driving experimental laboratories. Holds a Toronto doctorate and earlier UBC and Sharif degrees. Lila describes his chemistry role as in residence.

John Kim is publicly identified by Lila as President, Corporate Development. Previously led client development at General Catalyst after work at JPMorgan, Court Square and Kelso. Holds Brown and Harvard Business School degrees. This is the Lila corporate-development executive, distinct from the Presence AI co-founder and Contraline regulatory executive sharing his name.

Rie joined Augustine as CSO in May 2025. With more than 20 years’ experience in drug discovery and early-stage drug development, she is an experienced executive with a strong background in cardio-metabolic and inflammation-driven diseases as well as peptide therapeutics. Prior to joining Augustine, she served as the Chief Scientific Officer at Aelin Therapeutics, where she played a key role in developing a degrader platform based on induced protein aggregation to neutralize disease-causing proteins. Later, she spearheaded an entrepreneurial initiative advancing AI/ML-based solutions derived from Aelin Therapeutics technology. Rie spent the majority of her career at the peptide development specialist Zealand Pharma (CPH: ZEAL) where she worked across multiple functional areas, mainly focused on cardiovascular, metabolic and inflammatory diseases. She received her Master's in Biology and PhD at the Faculty of Medicine, University of Copenhagen. She is also a board member of the Peptide Therapeutics Foundation and a member of the DCAcademy Grant Committee (University of Copenhagen) and obtained her post doctorate in cardiovascular research.

Prior to joining Augustine, she was the CFO at Novadip having originally joined as Vice President, Finance and Administration in 2015. Before Novadip, Virginie was Head of the Finance Department in Belgium for AbbVie, where she transformed the department into a closer partner of regulatory, market access and commercial teams. Previously, Virginie was with AstraZeneca where she was Head of Finance in Belgium and worked at the European Headquarters. Virginie started her career with Deloitte in 2003. Virginie received her Master of Economics from Université Catholique de Louvain and a master’s in accounting and audit from Katholieke Universiteit Leuven, complemented by a management degree for the pharmaceutical sector.

Augustine Therapeutics NV is a Belgian biotechnology company founded in 2019 as a VIB and KU Leuven spin-off, based in Leuven with a Copenhagen subsidiary announced in 2025. It develops investigational small-molecule inhibitors of cytosolic histone deacetylase 6 (HDAC6) for neuromuscular, neurodegenerative and cardiometabolic diseases. Its scientific foundation includes Ludo Van Den Bosch’s research in axonal transport, peripheral neuropathies and Charcot-Marie-Tooth disease. The pipeline includes peripheral-restricted and brain-penetrant approaches, with potential CNS applications including ALS. These programmes do not establish therapeutic efficacy or regulatory approval. In May 2025, Augustine reported first dosing of AGT-100216 in a Phase I healthy-volunteer study. Its current website uses AGT-100XXX for an IND-enabling lead programme and lists additional discovery and lead-optimization programmes; dated trial announcements are therefore distinguished from present pipeline status. Gerhard Koenig has been CEO since January 2025. Published executives, directors, external scientific advisers and dated observer appointments are qualified separately. Financing includes a EUR 4.2 million seed in December 2019 and a June 2024 first Series A closing later restated to EUR 17.5 million. The March 2025 EUR 77.7 million final Series A total includes that earlier closing; its incremental cash allocation is undisclosed. Research grants and research support are recorded separately from equity, and award values do not establish payment dates.

Theodorus publishes Joke Vereecken with the following specifically scoped affiliation: Historical Fund IV team member (legacy own fund launch/about page; not asserted as current staff). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Telos Impact’s current own biography identifies her as Mental Health Fund Manager, having joined in February2026 after Droia Ventures, Theodorus and Carevest. Her Theodorus affiliation here is historical.

Theodorus publishes Lotfi Yelles Chaouche with the following specifically scoped affiliation: Historical Fund IV team member (legacy own fund launch/about page; not asserted as current staff). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes Béatrice Couture with the following specifically scoped affiliation: LPAC member — Teralys Capital (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes Daniele Carati with the following specifically scoped affiliation: LPAC member — Knowledge Transfer Office, Université libre de Bruxelles (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes François Bergeron with the following specifically scoped affiliation: LPAC member — MEDTEQ (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes Marie Bouillez with the following specifically scoped affiliation: Historical Fund IV team member (legacy own fund launch/about page; not asserted as current staff). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Pierre-Hugues Bonnefoy-Cudraz is identified in the current Belgian company registry as a permanent representative of a corporate director of Theodorus IV SA. This governance role is distinct from investment-team employment or personal investment.

Theodorus publishes Véronique Missout with the following specifically scoped affiliation: LPAC member — FSTQ (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes Ilan Zatalovski with the following specifically scoped affiliation: Investment Committee member — Funding Expert (committee/LP representative affiliation, not an employment claim); LPAC member — Funding Expert (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Based in London. Joined Vitruvian in 2019.

Based in Munich. Joined Vitruvian in 2026.

Based in Mumbai. Joined Vitruvian in 2024.

Based in Mumbai. Joined Vitruvian in 2021.

Based in Shanghai. Joined Vitruvian in 2015.

Based in London. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2012.

Based in London. Joined Vitruvian in 2007.

Based in London.

Based in London. Joined Vitruvian in 2026.

Based in Miami.

Based in London. Joined Vitruvian in 2009.

Based in London. Joined Vitruvian in 2024.

Based in Singapore. Joined Vitruvian in 2019.

Based in Mumbai. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2016.

Based in London. Joined Vitruvian in 2026.

Based in London. Joined Vitruvian in 2024.

Based in London. Joined Vitruvian in 2016.

Based in London. Joined Vitruvian in 2025.

Based in Stockholm. Joined Vitruvian in 2026.

Based in Stockholm. Joined Vitruvian in 2019.

Based in Mumbai. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2017.

Based in Munich. Joined Vitruvian in 2025.

Based in Miami. Joined Vitruvian in 2026.

Based in Munich. Joined Vitruvian in 2022.

Growth investor focused on consumer technology, data and analytics. Previously worked at Cinven and Goldman Sachs and holds an Oxford MA. Distinct from the Rapta director who co-founded Obsidian Security and Carbon Black. Ben Johnson is an Oxford University Innovation non-executive director and founding-team Partner at Vitruvian Partners in London, focusing on consumer technology, data and analytics. He previously worked at Cinven and Goldman Sachs and studied PPE at Magdalen College, Oxford. He is distinct from the existing Rapta director and Carbon Black/Obsidian Security co-founder with the same name.

Based in London. Joined Vitruvian in 2014.

Based in Miami. Joined Vitruvian in 2024.

Based in London. Joined Vitruvian in 2018.

Based in Miami. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2015.

Based in London. Joined Vitruvian in 2021.

Based in Stockholm. Joined Vitruvian in 2026.

Based in Munich. Joined Vitruvian in 2021.

Based in London.

Based in London.

Based in London. Joined Vitruvian in 2020.

Based in London. Joined Vitruvian in 2021.

Based in London. Joined Vitruvian in 2021.

Based in London. Joined Vitruvian in 2017.

Based in Stockholm. Joined Vitruvian in 2021.

Based in Miami. Joined Vitruvian in 2025.

Based in Munich. Joined Vitruvian in 2017.

Based in Madrid. Joined Vitruvian in 2021.

Based in London. Joined Vitruvian in 2024.

Based in Stockholm. Joined Vitruvian in 2023.

Based in London. Joined Vitruvian in 2017.

Based in Luxembourg. Joined Vitruvian in 2017.

Based in Miami. Joined Vitruvian in 2020.

Based in Mumbai. Joined Vitruvian in 2026.

Based in London. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2024.

Based in Singapore. Joined Vitruvian in 2021.

Based in London. Joined Vitruvian in 2025.

Based in London.

Based in London. Joined Vitruvian in 2019.

Based in London. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2008.

Based in London. Joined Vitruvian in 2019.

Based in Miami.

Based in London. Joined Vitruvian in 2018.

Based in London. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2007.

Based in Mumbai.

Based in London. Joined Vitruvian in 2023.

Based in London. Joined Vitruvian in 2022.

Based in London. Joined Vitruvian in 2026.

Based in Munich. Joined Vitruvian in 2024.

Based in London. Joined Vitruvian in 2020.

Based in Singapore. Joined Vitruvian in 2025.

Based in London. Joined Vitruvian in 2014.

Based in London. Joined Vitruvian in 2023.

Based in Miami. Joined Vitruvian in 2025.

Based in Munich. Joined Vitruvian in 2018.

Based in Miami. Joined Vitruvian in 2025.

Co-founder of Vitruvian with a focus on technology investments. Previously a global equity partner and European technology-investment leader at Apax; earlier worked in strategy consulting and automotive engineering.

Based in London. Joined Vitruvian in 2018.

Based in London. Joined Vitruvian in 2019.

Based in Stockholm. Joined Vitruvian in 2018.

Based in Stockholm. Joined Vitruvian in 2010.

Based in Dubai. Joined Vitruvian in 2026.

Based in London. Joined Vitruvian in 2025.

Based in Miami. Joined Vitruvian in 2024.

Based in London. Joined Vitruvian in 2011.

Anne-Sophie Bouvy is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution.

Cédric Slegers is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution. The enterprise register identifies him specifically as permanent representative of corporate director 0436.206.426, rather than an additional personal statutory director.

Emmanuel Terrasse is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution. The own 2024–2025 ESG report separately identifies him as chair of Sambrinvest’s ESG committee.

Ludovic Piérart is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution.

Anne Fally is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution.

Jean-Pol Detiffe is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution. His own OncoRNA biography identifies him as an industrial pharmacist, founder and former CEO of OncoDNA; this scientific entrepreneurship background is distinct from his Sambrinvest governance role.

Nathalie Draux is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution. Her own Quality Assistance biography separately corroborates her Sambrinvest board position. Quality Assistance’s current own biography names her CEO since 2023, following family-business service from 2001 and appointment as Director of Operations in 2016. It identifies pharmaceutical sciences/industrial pharmacy qualifications at UCLouvain and a 2015 Vlerick accelerated management programme.

Vittorio Lauriente is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution.

Simon Bullman is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution. Sambrinvest’s own 2018 appointment biography describes qualifications in law and management, leadership of an automobile dealership group from 1991 to 2017, and election as chair on November 16, 2018. Its November 2023 announcement confirms his renewed chairmanship.

Thibault Carrier is published in Sambrinvest’s current governance roster. The official Belgian enterprise register corroborates this legal governance appointment, separate from investment-team employment and personal investment attribution.

Loris Jeandriens is published as Finance Controller in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Lucile De Windt is published as Accountant in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Ornella Di Piazza is published as Executive Assistant in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Caroline Stevens is published as Investment Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Emily Degrande is published as Communication manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Fabrice Carosella is published as Investment Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Micheline Streel is published as Investment Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Thibaut Damanet is published as Investment Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Jason Ranwez is published as Facility Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Alexandre Cloquet is published as Real Estate Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Alessandro Brusadelli is Scientific & Regulatory Specialist at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification PhD.

Alessandro di Pietro is Head of Business Development at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MBA.

Alexander Boudewijn is Privacy Research and Grants at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification PhD.

Andrea Corbetta is RWE Data Scientist at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification PhD.

Andrea Coser is Head of AI at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification PhD.

Antonio Arezzo is Chief Financial Officer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Arianna Bertolani is Scientific & Regulatory Manager at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification PhD.

Borut Svara co-founded Aindo in2018 with Daniele Panfilo and Sebastiano Saccani. The company’s October18,2023SeriesAannouncement identifies him as CTO. This is a dated historical affiliation: the current official directory names Simone Ziraldo as CTO and does not list Svara; no departure date or continuing operating position is inferred.

Davide Ceschia is Frontend Developer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification HS.

Davide Ruffo is Chief Corporate & Business Development Officer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification LLM.

Deborah Marazzina is Executive Assistant at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification BA.

Edoardo De Stalis is Graphic Designer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification BA.

Elisa Scandariato is Head of Customer Delivery & Operations at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Francesca Dreossi is Head of People & Culture at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification HS.

Francesco D'Orlandi is DevOps Engineer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification BSc.

Giacomo Creta is Public Sector & Healthcare Business Lead at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Giovanni Zanin is Data Scientist at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Greta Ellero is People & Culture Specialist at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification BA.

Jacopo Zambelli is Partner Business Development Analyst at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification BSc.

Luka Giga is Backend Developer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification HS.

Marco Romanelli is Backend Developer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Michele Berti is Technical Project Manager at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Octavio Pomponio is Data Scientist at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification PhD.

Pierandrea Sartori is ML Scientist at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Sabrina Zinutti is Communication & Events at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MA.

Sebastiano Saccani co-founded Aindo in2018 and currently leads product and R&D. The company develops synthetic-data and AI evidence infrastructure for privacy-sensitive applications. The official current team directory identifies a doctorate; the2023companyannouncement formerly titled him Head ofR&D.

Simone Ziraldo is Chief Technology Officer at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification PhD.

Tania Bratoni is Senior Financial Controller at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification MSc.

Vanessa Cocca is DPO at Aindo, the Trieste company developing generative-AI synthetic data and healthcare evidence infrastructure. The current official directory identifies the qualification LLM.

Aindo S.p.A. is a Trieste, Italy artificial-intelligence company founded in2018 from SISSA research. Its official legal footer identifies VAT01313960328, REA TS203253 and registered address LocalitàPadriciano99; historical AindoSrl and currentSpA represent the same source-qualified business. Aindo develops generative-AI synthetic-data technology that models statistical characteristics of sensitive datasets for research and data sharing. Its current healthcare work includes real-world evidence, synthetic external control arms, public-health planning and specialised clinical language models; it also serves finance and public-sector users. These are AI/data infrastructure applications, without an inferred neuroscience therapy approval or proof of clinical efficacy. The company reports Europrivacy and ISO certifications; product privacy and regulatory statements are attributed to company publications. Its current native official directory publishes29 people across executives, scientific/regulatory, machine learning, privacy research, data science, engineering, commercial, people, finance and operations functions. Cofounders DanielePanfilo and SebastianoSaccani remain listed; third cofounder BorutSvara’s CTO affiliation is documented inOctober2023 and distinguished from current CTOSimoneZiraldo. Actual disclosed equity financing is EUR2.8M from managed VertisVenture3TechnologyTransfer announcedNovember30,2021 and EUR6M SeriesA closedOctober18,2023 led byUnitedVentures withVertis follow-on. The2021–2022timeline’s EUR3M rounded historical investment is not added as a new round. Public research awards and expressly received grants are recorded separately: EU SydAi grant agreement101218531 was signedJune20,2025 with exact contributionEUR2,080,085.71, rounded by thecompany to2.1M. Signing/projectstart/award announcements do not prove completed cash disbursement; possible EIB co-investment is not an actual equity cheque. FVG historical cash grants and other programme awards are distinguished from eligible project costs and budget shares. Nominal paid-in share capitalEUR88,105 is not financing. Commercial/customer and research collaborations are not inferred equity investments.

Daniele Panfilo co-founded Aindo in2018 and serves as its Chief Executive Officer. Aindo originated at SISSA in Trieste and develops generative-AI synthetic data for privacy-sensitive healthcare, financial and public-sector analysis. The current directory identifies a doctorate; his own2023fundraising statement describes the company’s objective of making restricted structured data usable for AI.

Isabelle Berkhoff y Garcia is published as Real Estate Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Theodorus publishes Michel Lussier with the following specifically scoped affiliation: Investment Committee member — Medtech expert (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Caroline Hazard is published as Project Manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Elisabeth de Halleux is published as Investment manager in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Joachim Colot is published as Head of Legal in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Theodorus publishes Alexandre Franco with the following specifically scoped affiliation: Investment Committee member — Funding Expert (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Nicolas Winand is published as Chief Financial Officer in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Maxime Van Der Schrick is published as Chief Operating Officer in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Theodorus publishes Barbara Roose with the following specifically scoped affiliation: Investment Committee member — Finance.Brussels (committee/LP representative affiliation, not an employment claim); LPAC member — Finance.Brussels (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Own published biographical background: Finance.Brussels Barbara ROOSE is Investment Manager at Société Régionale d'Investissement de Bruxelles (SRIB), acting as key player in the economical development of Brussels area. Barbara Roose is Director of numerous Brussels company as XXX

Helena Pozios is published as Head of Venture Capital in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments. Sambrinvest’s own September 2024 introduction describes biotechnology engineering, a master’s degree in corporate finance and prior equity-investment experience. The current directory labels her Head of Venture Capital; the firm’s September 2024 announcement appointed her Chief Investment Officer, also used in March 2025. Both published titles are retained with their source context; no exact subsequent title-transition date is inferred. Theodorus publishes Helena Pozios with the following specifically scoped affiliation: Investment Committee member — Sambrinvest (committee/LP representative affiliation, not an employment claim); LPAC member — Sambrinvest (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Xavier Daive is published as General Secretary in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments.

Grégoire Dupuis is published as CEO in Sambrinvest’s current team directory. Sambrinvest is the public-private Charleroi regional investor providing equity and financing to startups and SMEs, including life-science and industrial innovation companies. This professional affiliation does not establish personal cash investments. The Belgian official enterprise register records responsibility for daily management from December 1, 2022.

Theodorus publishes Claude Jottrand with the following specifically scoped affiliation: Investment Committee member — Funding Expert (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Own published biographical background: Funding Expert Claude JOTTRAND has an extensive Belgian and foreign M&A expertise gained through his experience of over 20 years at Banque Degroof, starting as a Financial Analyst and in latter years, as a Director of the Investment Banking Department. Claude JOTTRAND is a member of various boards as Non-Executive Director. He is the Chairman of the Board of Verlinvest S.A. and has served as Non Executive Director and a Member of the Compensation Committee of Atenor SA.

Sambrinvest is a public-private regional investor based in Charleroi, Belgium, providing equity capital and financing to startups, growing SMEs and businesses undergoing succession. Its exact legal company is Société de Développement et de Participation du Bassin de Charleroi, abbreviated Sambrinvest, a Belgian société anonyme with enterprise number 0427.908.867. The official Belgian enterprise register confirms its January 9, 1985 establishment and current office at 6 Quai Arthur Rimbaud, Charleroi. Its own historical annual report describes an initial partnership between the Walloon Region and private shareholders. The current strategy covers life sciences, industry, materials, agrifood and structural real-estate projects. Its NEUVASQ investment supports a blood-brain-barrier therapeutic platform, while the June 2025 Elkedonia seed financing supports research on depression and neuropsychiatric disease. These are research-stage company investments, not evidence of clinical approval or treatment efficacy. Its own portfolio directory mixes participated companies and ecosystem partners; a logo listing alone is not treated as a cash equity transaction. Sambrinvest publishes 19 operating staff and 12 governance members. Grégoire Dupuis is CEO, Helena Pozios Head of Venture Capital and Simon Bullman board chair. The official register identifies Cédric Slegers as permanent representative of the corporate director Cometsambre, rather than an additional individual statutory director. Shared Wallonie Entreprendre governance people remain separate affiliations. Its own website reports more than EUR200 million under management and nearly 300 SMEs in portfolio; these figures are not a new fund close or cash financing. European Venture Capital for Charleroi is a EUR28.2 million public co-funded investment programme launched in June 2024 with FEDER and Walloon Region support, distinct from a conventional private LP fund closing. Historical corporate financing vehicles include Fonds de Capitaux d’Amorçage, Fonds de Capital à Risque Objectif n°1 and the leasing/property subsidiary Sambrelease. Incorporation dates, corporate capital, investment decisions and financing plans are not recorded as undisclosed external fund closes.

Theodorus publishes Emmanuel Caeymaex with the following specifically scoped affiliation: Investment Committee member — Pharma Expert, UCB (committee/LP representative affiliation, not an employment claim). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Own published biographical background: Pharma Expert, UCB Emmanuel CAEYMAEX is Executive Vice President and Immunology Patient Value Unit Head at UCB. He leads the understanding of patient needs, the development and commercialization of solutions. Over the last 20 years Emmanuel has been instrumental in advancing UCB’s transformation into a global biopharma company focused on patients with severe diseases. The legacy Theodorus UCB title is superseded by UCB’s current primary directory: Executive Vice President, Patient Evidence, effective January2026.

Theodorus publishes Patricia Escoffier with the following specifically scoped affiliation: Principal (published Theodorus platform team; Fund IV-specific appointment not independently dated). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes Elise Napolitano with the following specifically scoped affiliation: Associate (published Theodorus platform team; Fund IV-specific appointment not independently dated). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes Jean Van Nuwenborg with the following specifically scoped affiliation: Strategic Advisor (published Theodorus platform team; Fund IV-specific appointment not independently dated). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date.

Theodorus publishes Adrien Van der Borght with the following specifically scoped affiliation: Principal (published Theodorus platform team; Fund IV-specific appointment not independently dated). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Own published biographical background: Principal Belgium Adrien joined Theodorus in 2018 to help support portfolio companies with their strategic vision. He has previously build up expertise in strategy and deal structuring respectively at the Boston consulting Group and Lazard. He holds a degree in Business Engineering from the Solvay Brussels School of Economics and Management and the National University of Singapore.

Theodorus publishes Théo Risopoulos with the following specifically scoped affiliation: Partner (published Theodorus platform team; Fund IV-specific appointment not independently dated). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Own published biographical background: Partner Théo joined Theodorus in 2018 to help on the screening, assessment and execution of investment opportunities. He has previously built up expertise in strategy and due diligence with private equity and industrial clients at Roland Berger. He holds a master degree in Finance from the Solvay Brussels School of Economics and Management.

Theodorus publishes Olivier Belenger with the following specifically scoped affiliation: Managing Partner (published Theodorus platform team; Fund IV-specific appointment not independently dated); Partner (published Theodorus platform team; Fund IV-specific appointment not independently dated). Fund IV is a distinct 2018 investment vehicle, and shared-platform directory listings do not independently establish a direct Fund IV employment contract or exact appointment date. Own published biographical background: Managing Partner Olivier cumulates 20 years of experience in Venture Capital and financing structures. Deeply committed to innovation and entrepreneurship, Olivier has dedicated his carreer to improving access to venture capital in Belgium. Olivier is the founder of EEBIC Venture, an investment platform with more than 80 M€ under management. Olivier is also the founder of the Theodorus funds and has served as managing director since 2003. Olivier holds a Master in Law from the Université Libre de Bruxelles (Belgium). ob@theodorus.be

Nikos Theodosopoulos joined Hercules’ board in 2023. His career includes NT Advisors, technology equity research at UBS and Bear Stearns, and communications work at AT&T Bell Labs. He studied engineering at Columbia and Stanford and completed an MBA at NYU.

Wade Loo joined Hercules’ board in July2021. His background includes an audit-partner career at KPMG and finance, audit and governance responsibilities. He studied accounting at Denver.

Alfred B. Fichera joined Hercules’ board on September17,2026. He worked at KPMG during 1982–2019, including alternative-investments leadership. He also serves as a Warburg Pincus Access Fund director and provides asset-management expertise. He studied accounting at Merrimack and is a CPA.

Emanuele Levi is CEO and General Manager of CDP Venture Capital, appointed in May2025. He studied business economics in Turin and corporate finance at London Business School. His career began with Credito Italiano in1993, followed by Bain & Company and Lazard investment banking. From2000 he specialized in venture investing at Pino Venture and360 Capital, where he was a General Partner until2025. These prior positions are historical; the primary current manager directory confirms his CDP leadership.

Anna Lambiase is the published Chair of CDP Venture Capital. An equity-capital-markets and sustainable-finance professional, she founded IRTOP Consulting in Milan in2001 and developed the PMI Capital investor data platform. Her work includes IPOs, alternative finance, investor reporting, small-cap equity research and ESG advice. She holds doctoral finance qualifications associated with Politecnico di Milano and University of Pavia. The manager’s biography identifies her Invitalia board service as2023–2025.

Stefano Tomei is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Investment Manager (Artificial Intelligence). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Roberto Ceraolo is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Data Scientist - Associate (Artificial Intelligence). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Theodorus IV is the Belgian–Quebec venture fund launched in October 2018 within the Université libre de Bruxelles spin-off ecosystem. It backs seed and early-stage proprietary technologies in life sciences, medical technology, digital applications and engineering. Its portfolio includes NEUVASQ’s blood–brain-barrier therapeutics, DrugBank’s biomedical data platform, and other AI, therapeutic discovery and digital-health businesses. The exact Belgian vehicle is THEODORUS IV SA, active enterprise 0707.902.931, which commenced on 8 October 2018. Its own site and institutional LP SFPIM report a €42 million fund corpus. This differs from Belgian registered share capital of €32.875 million and the historical platform-wide €70 million AUM. Seido Capital reports taking over Fund IV’s management contract in 2025 for divestment. The Belgian registry separately identifies Bizitip as delegated corporate director, represented by Olivier Belenger, since 21 May 2025; no legal equivalence between Bizitip and Seido is assumed. Funds I–III, proposed Fund V and the new Seido fund are separate vehicles. The profile distinguishes current legal director representatives, the published shared-platform investment and advisory roster, LP committee representatives, and historical launch-team members. A shared-platform listing does not independently establish direct Fund IV employment. Authentic primary-source portraits are included where available; generic demo photos are excluded. Exact final fund close day and the Canadian parallel legal subscriber remain unverified.

Carolina Beniamina Rutta is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Investment Associate (Artificial Intelligence). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Matteo La Naia is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Partner (Artificial Intelligence). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Marco Allegretti is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Partner (Artificial Intelligence). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Vincenzo Di Nicola is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Partner – Responsabile del Fondo (Artificial Intelligence). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Luca Baratta is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Analyst (Digital Transition). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Andrea Gracis is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Investment Manager (Digital Transition). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Davide Karapedian is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Associate (Digital Transition). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Stefano Mascetti is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Investment Manager (Digital Transition). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Luca Zabaione is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Investment Manager (Digital Transition). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Paola Deidda is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Investment Manager (Italia Venture II). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Alessandro Angeletti is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Investment Manager (Italia Venture II). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Ersilia Rendola is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Partner (Italia Venture II). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Federico Lanciano is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Partner - Responsabile del Fondo (Italia Venture II). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Francesca Pisani is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Associate (Boost Innovation). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Andrea Resmini is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Partner (Boost Innovation). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Arianna Zola is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Analyst (Large Ventures). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Luciano Ferraro is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Associate (Large Ventures). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Niccolò Mussi is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Investment Manager (Large Ventures). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Gianmarco Del Bono is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Senior Investment Manager (Large Ventures). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Davide Opromolla is a published team member of CDP Venture Capital SGR S.p.A. The current native directory lists Partner (Large Ventures). The named fund affiliations are investment-team responsibilities within the Italian venture manager, which supports technology commercialization and innovative startups through direct funds and funds of funds. Appointment dates and education are not inferred where unpublished.

Thomas J. Fallon joined Hercules’ board in 2014. He became an executive vice president of business development at Sanmina in 2022 and previously led Infinera as CEO during 2010–2020, following work at Cisco. He studied mechanical engineering and business at Texas.

Gayle Crowell joined Hercules’ board in February2019. Her earlier career includes operating consultancy at Warburg Pincus during 2002–2019 and software leadership at Oracle and Epiphany. She studied education at Nevada, Reno.

DeAnne Aguirre joined Hercules’ board in June2022. She retired as PwC’s North American strategy managing partner in 2020 and previously held strategy and technology leadership roles at Booz. She studied mathematics at Fort Hays and business at Stanford.

Robert P. Badavas has served on Hercules’ board since March2006 and as chair since May2019. His career includes Petros Ventures, leadership of PlumChoice and TAC, operating responsibilities at Atlas and work at PwC. He studied accounting and finance at Bentley.

Max Krieg is a life-sciences vice president based in New York. He joined Hercules as a senior analyst in 2022 and became a vice president in 2026. He previously worked in SVB health-technology and medical-device underwriting and studied economics and statistics at Haverford.

Alexandra Henderson is a life-sciences vice president based in Boston. She joined Hercules in October2020 and became a vice president in July2025. She previously completed Santander credit training, studied science/business and English at Notre Dame and earned the CFA designation in 2022.

Greyson Zatzick is a technology vice president based in San Francisco. He joined Hercules in 2021 following investment-banking work. He studied economics and Spanish at Middlebury.

Tess Alonge is a technology vice president based in New York. She joined Hercules as an analyst in July2020 and became a vice president in July2025. Her earlier experience includes Jefferies trading operations and GE’s finance program; she studied finance and social entrepreneurship at Northeastern.

John O’Leary is a life-sciences vice president based in San Mateo. He joined Hercules in 2020 following healthcare underwriting at SVB. He studied economics and French at UCLA.

Briana Gironda is a life-sciences principal who joined Hercules in 2020. She previously worked at MidCap Financial and studied chemistry and mathematics at William & Mary.

Eddie Lopez is a technology principal based in San Mateo. He joined Hercules in 2021 after five years in Wells Fargo corporate technology banking. He studied economics at Wesleyan and also serves as treasurer of SomosVC.

James Feldman is a technology principal based in Boston. He joined Hercules as an analyst in 2018 and became a principal in 2025. He previously worked in PNC underwriting and studied finance at Ohio State.

John Miotti is a principal in life sciences based in New York. He joined Hercules as an analyst in 2017 and became a principal in 2023. He studied economics and English at Boston College.

Joshua Coleman is a credit managing director based in New York. His earlier career includes Barings Capital Solutions fund finance and Medley Capital portfolio management and workouts. He studied mathematics and economics at Canisius.

Paul Sohn is a managing director in credit at Hercules. His published role covers underwriting and portfolio oversight. Further personal education or employment history is not asserted beyond the current primary directory.

Zach Norris is a credit managing director based in Denver. His prior work includes senior credit responsibilities in SVB corporate banking and restructuring, as well as advisory-services workout assignments.

Brian Powers joined Hercules in 2023 as a managing director in life sciences. His earlier career includes ten years at SVB. He studied finance at Iowa and holds the CFA designation.

Jeffrey Ralto is a life-sciences managing director who joined Hercules in September2021 after SVB healthcare banking. He also previously worked as a Hercules analyst. He studied finance at Northeastern and holds the CFA designation.

Michael McMahon joined Hercules in 2023 as a life-sciences managing director based in Boston. He previously spent eighteen years at SVB working with secured and mezzanine loans. He studied economics at Tufts.

Ella Adhanan, also identified in her biography as Ella-Tamar Adhanan, is a technology managing director based in New York. Her earlier work includes SVB’s US–Israel technology banking, international venture relationships, Morgan Stanley and the Israeli embassy. She studied economics at Maryland.

Noah Carville is a technology managing director based in Boston. He joined Hercules in January2016 following UBS credit and Manulife business experience. He studied economics at Northeastern; the current directory supersedes the older principal title in his biography.

Yong Yang Yap is listed by Novo Holdings as Associate in Planetary Health Investments. Further biography is not published on the reviewed profile.

Young-Hun Kim joined Venture Investments in 2025 as Senior Associate and is based in San Francisco. Prior to Novo, Young-Hun was a Senior Associate at Citadel Global Equities where he covered public companies in the Medtech, Animal Health and Dental sectors. Before Citadel, Young-Hun began his career in Healthcare Investment Banking at Citigroup.  Young-Hun holds a MSE and BSE in Bioengineering from the University of Pennsylvania, and a BSE in Finance from the Wharton School.

Morgan Russom is a technology managing director based in New York. He joined Hercules in 2017 after Bridge Bank and AGC Partners. He studied economics at Harvard.

Member of the Novo Holdings Board since 2018. Chair of the Novo Holdings Audit Committee. Viviane Monges was born in 1963 and is a French national. She received an MBA from Ecole Supérieure de Commerce de Paris (ESCP). In the beginning of her career, she worked across a wide variety of roles in Asia, Latin America, Europe and the United States. Viviane Monges has over 30 years of financial management experience, predominantly in the pharmaceutical industry. She joined Wyeth Pharmaceuticals Inc. in 1997 and held several leadership roles, including CFO of the Europe Region unit and CFO of the Global Pharma Business unit. From 2006 to 2010, Viviane Monges was with Novartis A/G as Europe CFO and then as Global Division CFO of the OTC Division. In 2010, she joined Galderma S.A., a multinational dermatology company as Group CFO, which was later acquired by Nestlé S.A. From 2015 to 2018, she served as CFO of the Nestlé Business Excellence Division. Since then, she has been serving on the boards of several health care companies.     Other Board Positions and Management Duties: Board Member and Chair of the Audit Committee, Ferring Pharmaceuticals, Switzerland Board Member and Chair of the Audit Committee, ADC Therapeutics, Switzerland Board Member and Chair of the Audit Committee, Pharvaris, the Netherlands Board Member and Member of the Audit Committee, BioMerieux, France

William Møller is listed by Novo Holdings as Technical Lead Data & Platform Engineer in Finance & Operations. Further biography is not published on the reviewed profile.

Valdemar Lund-Frank is listed by Novo Holdings as Junior Analyst in Seed Investments. Further biography is not published on the reviewed profile.

Victor joined Novo Holdings in March 2024 as a Vice President in Capital Investments, where he is responsible for analyzing direct public investment opportunities. Prior to joining Novo Holdings Victor was a Portfolio Manager at Snowball Capital and Secure Spectrum Fondsmægler Selskab. Victor holds a MSc in Economics from the University of Copenhagen.

Victoria joined Novo Holdings A/S in July 2026 as PMO Specialist in the Strategy Office, where she is part of the Programme & Projects team. Prior to joining the Programme & Projects team, Victoria held the position of Junior Analyst in the People & Organisation team, where she supported the Talent and Operations teams across a range of operational and people-related initiatives. Victoria holds an MSc in Business Administration and Psychology.

Vikas joined Novo Holdings in November 2024 as a Machine Learning Engineer within the Digital and BI team under Finance & Operations. In this role, he is responsible for developing and deploying advanced machine learning and generative AI solutions to support digital transformation, driving innovation and solving complex business challenges through data-driven approaches. Prior to Novo Holdings, Vikas applied his expertise at organizations such as Ønskeskyen, Wunderman Thompson MAP (VML MAP), and Nexcom A/S, where he built applications that integrated cutting-edge machine learning technologies, including Generative AI, Large Language Models (LLMs), and cloud-based solutions. He holds a Ph.D. in Computational Biology from the University of Southern Denmark (SDU) in Odense.

Mike Willard leads sponsor finance as a Hercules managing director. He previously spent seventeen years in SVB sponsor finance and worked at Wells Fargo. He studied at Saint Michael’s and completed an MBA at Clarkson.

Adam Soller is a life-sciences managing director based in Washington, DC. He previously held a managing-director role at Oxford Finance and worked at Capital Automotive REIT. He attended Virginia Military Institute.

Trey has been involved in healthcare principal investing and advisory since 2018. Prior to Novo Holdings, he served as a private equity investment professional at Water Street Healthcare Partners and Silver Oak Services Partners. Trey began his career in the healthcare investment banking group at Citigroup. He graduated from the University of Michigan with a BSE in biomedical engineering as well as a BBA in finance from the Stephen M. Ross School of Business.

Tugrul Ozdemir joined Seed Investments in May 2022 as an Associate. Previously, Tugrul worked as a postdoctoral researcher in the Department of Pharmacology at the University of Oxford, and as a VC fellow at Ysios Capital, where he analyzed deal flow opportunities and supported due diligence and management processes of biotechnology companies at various stages of development. Tugrul has extensive research experience in molecular, cognitive and systems neuroscience laboratories, has published articles in high impact peer reviewed journals and provided external consultancy to biotechnology companies and venture capitals. Tugrul was trained as a molecular biologist in Turkey and the USA, and holds a PhD in neuroscience from the Medical University of Vienna. He is the recipient of a Stanford Conte Scholarship, FENS-IBRO Cajal Stipend, Alzheimer’s UK Early Career Researcher Award, Constantin von Economo Prize for Brain Research and Junior Research Fellowship at Wolfson College, Oxford.

Tuomas joined Novo Holdings A/S in January 2022 as Principal in Principal Investments. He participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments. Prior to joining Novo, Tuomas was at G Square in London working on European healthcare private equity investments. Before this, he was investing in private equity and growth capital investments in the healthcare and technology sectors at Novator Partners based in London. Tuomas started his career with Morgan Stanley focusing on M&A transactions. Tuomas holds a BSc and an MSc in Finance from Aalto University School of Business.

Ulla joined Novo Holdings A/S in December 2025 as Salesforce Product Owner. She is responsible for the Salesforce platform covering implementation, development and continuous enhancement to support Novo Holdings’ digital strategy. Ulla brings extensive experience from delivering Salesforce solutions in large international organizations, combined with strong capabilities within commercial excellence, sales processes, training and change management. Prior to joining Novo Holdings A/S, Ulla worked as Lead Salesforce Business Consultant and Manager at Fluido. Before that she held CRM and commercial leadership roles at TDC, PostNord, Ørsted and Demant. Ulla holds an MSc in Strategy and Marketing from Copenhagen Business School and is certified in Salesforce, ITIL4 and ADKAR Change Management.

Tom joined Novo Holdings A/S in September 2024 as an Associate in Principal Investments. He participates in deal sourcing and execution as well as in managing the existing portfolio of investments. Prior to joining Novo Holdings A/S, Tom worked as an Investment Banking Associate at Jefferies in London, focusing on buy-side and sell-side M&A advisory within the Healthcare industry. Tom holds an MSc in Finance and Private Equity from the London School of Economics and a BSc in International Business from Grenoble École de Management.

Member of the Novo Holdings Board since 2025. Torsten Sløk was born in 1970 in Denmark and is a US citizen. Torsten Sløk is a world-renowned economist, with his expertise and insights regularly cited in top-tier publications both across Scandinavia and globally. Since 2020, he has served as Chief Economist of Apollo Global Management, where he leads Apollo's macroeconomic and market analysis across the platform and advises the company’s executive leadership, investment teams, and clients as a trusted voice for investors. Prior to joining Apollo, Torsten worked for 15 years as Chief Economist at Deutsche Bank where his team was top ranked in the annual Institutional Investor survey for a decade. Prior to joining Deutsche Bank, Torsten worked at the IMF in Washington, DC and at the OECD in Paris. Torsten Sløk has a Ph.D in Economics and has studied at the University of Copenhagen and Princeton University. He has published numerous journal articles and reviews on economics and policy analysis and is widely regarded for his sharp real-time analysis and forward-looking perspective on global markets.

Ruslan Sergeyev is a technology managing director based in New York. His background includes Stifel venture lending, Pacific Western credit, Golub Capital and Bank of America leveraged finance. He studied finance at Penn State.

Tina joined Novo Holdings A/S in September 2026 as Head of Accounting.  Tina joined Novo Holdings A/S in September 2026 as Head of Accounting. She joins from Ferring Pharmaceuticals A/S, where she served as Accounting & Reporting Manager. Earlier in her career, she was Global Accounts Receivable Manager at Hottinger Brüel & Kjær A/S and Director of Global Accounting Front Office at LEO Pharma A/S. She began her career at Coloplast A/S in roles spanning accounting, accounts receivable and team management. Christina has a degree in business economics in internal and external accounting from Helsingør Business School.

Tobias Kokansky Andersen is listed by Novo Holdings as Associate in Capital Investments. Further biography is not published on the reviewed profile.

Thomas joined Novo Holdings in 2017 and is Partner in the Planetary Health Investments team where he also oversees the Nordic early-stage activities. Prior to joining Novo Holdings, Thomas worked in business development at Novozymes where he introduced advanced yeast technology to the biofuel industry and built a portfolio of biochemical projects. Earlier in this career, he was part of the venture capital backed start-up company Fluxome Sciences. He also held positions in biotechnology research and process engineering at Toftejorg (now Alfa Laval) and the Carlsberg Breweries. Thomas holds a PhD in Metabolic Engineering and a MSc in Chemical Engineering from the Technical University of Denmark as well as graduate diplomas in Business Administration (Marketing Management and Finance) from Copenhagen Business School.

Thore joined Novo Holdings A/S in April 2024 as Head of Digital. He leads the digital transformation of Novo Holdings, drives the cultural shift and advances Novo Holdings digital capabilities to a level of recognized international authority in the investment space. Prior to joining Novo Holdings A/S, Thore worked as Senior Director at ATP with responsibility of New Tech, Innovation, advanced analytics, automation, digitalization and business intelligence. Thore holds a BSc and MSc from Aarhus University and a MSc in Business Development from Copenhagen Business School.

About Tim Robinson UK citizen Board positions Tim Robinson is currently serving as Lead Non-Executive Board Member at the UK Home Office. Career highlights 2025 - Chair, Single Use Support, Austria 2023 - Lead Non-Executive Board Member, Home Office, UK 2022 - Trustee, Place2B, UK 2021 - 2023   Chairman, Board of Directors, LGC, UK 2013 - 2021 Chief Executive Officer, LGC, UK Education Tim Robinson holds a BSc (Hons) degree in Physiology from Leeds University.

Tom Hertzberg is a managing director in life sciences at Hercules. His earlier career includes fifteen years at Silicon Valley Bank in healthcare and life-sciences banking. He studied business administration at Denver.

Theo Lundberg joined Seed Investments in 2024 and focuses on early-stage investments at the intersection of quantum technologies, life sciences and AI.  Prior to joining Novo Holdings, Theo built and incubated AI and software companies at Sutter Hill Ventures, where he was responsible for supporting Observe, Lacework, EdgeGuardian, and a stealth AI company. His past experience also includes management consulting with Boston Consulting Group, founding and leading several award-winning non-profits and ventures. Theo holds a PhD in Quantum Computing from the University of Cambridge and has more than 5 years of semiconductor and quantum physics research experience from Harvard University, UC Berkeley, IBM and the University of Cambridge. In 2020, he was one of 24 PhDs globally to be awarded the prestigious IBM PhD Fellowship for his research.

James Downing joined Hercules in November2021 as a managing director for Europe, based in London. His prior career includes venture relationships at SVB and relationship leadership at Barclays. He studied law at De Montfort.

Member of the Novo Holdings Board since 2023. Member of the Novo Holdings Remuneration & Nomination Committee. Susanne Schaffert was born in 1967 and is a German national. She has a strong scientific academic background and holds a PhD and a Diploma in Chemistry (MSc) from the Institute of Organic Chemistry, University Erlangen in Germany, and has completed the Executive Leadership Program and Executive Finance Leadership Program at Harvard Business School. In 2019-2022, Susanne Schaffert was President at Novartis Oncology in Basel, Switzerland, and has had a number of significant roles within the Novartis Group, including European General Manager of Novartis Oncology, Global Head of Investor Relations, and Global Franchise Head Immunology and Transplantation, as well as Global Brand Director. She holds a proven record of broad leadership and P&L experience on regional- and global level within biotech, pharmaceuticals, specialised care and oncology, and has had a number of Board positions within EFPIA, Novartis and JV GSK-Novartis Consumer Health. Other Board Positions and Management Duties: Board Member of BioNTech SE, Germany (public) Board member of Merck KgA Supervisory Board (public) and Board of Partners, Germany (non-public) Board Member of ARTBio, USA (non-public)  Board Member of Vetter Pharma, Germany (private) Board Member of Incyte, USA (public) until April 2026 Board Member of Galapagos, Belgium (public) until October 2025

Sussie joined Novo Holdings A/S in January 2023 as Board Assistant and is part of the Legal Team. In her role, she supports the Board of Directors and assist the Company Secretary with all board-related activities in Novo Holdings. Prior to joining Novo Holdings A/S, Sussie worked within the insurance industry at the Codan Group, where she was part of the Scandinavian Group Legal function for 15 years. Her most recent role has been as Deputy Company Secretary for the regulated operational insurance companies within the Codan/Alm. Brand Group. During her earlier career, Sussie worked as Paralegal at Eversheds Law Firm, Copenhagen Office. Sussie holds a Bachelor of business languages, English and French, from the University of Southern Denmark, as well as a degree as Paralegal and Legal Secretary from the Institute of Law (Jurainstituttet) and the University of Copenhagen.

Tania joined Novo Holdings A/S in August 2024 as Senior Partner in the Principal Investments team. Prior to Novo, Tania was a partner in the Private Equity team at BC Partners, covering the healthcare sector. She joined from Blackstone, where she looked after healthcare investments in Private Equity in Europe. Tania started her career at Goldman Sachs in the M&A team in London and Paris. Tania graduated from Ecole des Hautes Etudes Commerciales (HEC Paris).

Greg Peterson is a technology managing director who joined Hercules in 2016. He previously worked at East West Bank, SVB, Bridge Bank and Luxembourg’s economy ministry. He studied economics at Cornell and holds the CFA designation.

Søren joined Novo Holdings in June 2020 as Senior Partner in Capital Investments. Søren holds a graduate degree with a major in Finance from Copenhagen Business School (CBS), Denmark. Prior to joining Novo Holdings, Søren was employed at Industriens Pensionsforsikring A/S and Danske Bank.

Stine joined the People & Organisation team in 2021 as Head of Talent and Strategic Projects, responsible for Talent Attraction and Development, People related strategy and workforce planning, as well as several employee experience projects, including Business Partnering, culture, performance management process, engagement and DE&I. Prior to joining the P&O team, Stine was the Head of Project Office in Novo Holdings since 2018. Before Novo Holdings, Stine spent six years as a management consultant in Bain & Co with main focus on strategy projects and due diligences. Prior to this Stine worked in investment banking in FIH Partners. Stine holds a BSc in Economics and Business Administration and an MSc in Finance and Accounting from Copenhagen Business School.

Susan Chen joined Venture Investments in 2022 as an Associate. Previous to that, Susan was an Associate at Decheng Capital where she has helped make investments across therapeutics, medtech, and life science tools companies. Prior to Decheng, Susan was a Consultant at L.E.K. Consulting where she worked with pharmaceutical and biotech clients to identify growth strategies and assess business development opportunities. Susan holds a PhD in Genetics, Cell Biology, and Biochemistry from University of California, San Francisco, and a BS in Bioengineering and BA in Molecular Cell Biology from University of California, Berkeley.

Søren joined Novo Holdings A/S in November 2019 as Principal in Principal Investments, taking part in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings, Søren spent more than 10 years at SEB Corporate Finance in Copenhagen focusing primarily on buy- and sell-side M&A advisory in addition to equity capital market transactions. Søren holds a BSc in Business Administration from Aarhus University and an MSc in Finance and Accounting from Copenhagen Business School.

Michael Bowden manages portfolios across Hercules’ technology and life-sciences activities. He joined as an intern in 2007 and became a managing director in 2019. His earlier experience includes Credit Suisse HOLT and Bristol Myers; he studied finance at Northeastern.

Søren joined Novo Holdings A/S in May 2017 as Associate General Counsel and takes part in handling all legal matters within the company, including in particular mergers & acquisitions, corporate law and general contract matters. Prior to joining Novo Holdings A/S, Søren was employed with Maersk Oil for two years where he advised the business on mergers & acquisitions, oil and gas contracts and general corporate matters. Before that, Søren worked for nine years as a lawyer with the law firm Bruun & Hjejle in Copenhagen, where he specialized in mergers & acquisitions and capital markets (equity and debt), and as foreign lawyer at the law firm Holland & Knight in New York. Søren holds a Master of Laws from the University of Copenhagen (2006) and an LL.M. from New York University (2011), where he focused on corporate law and had classes at the law school as well as the Stern business school. He is a member of the Danish Bar Association.

Søren joined Novo A/S in 2011 as Managing Investment Director of Seed Investments. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Seed Investments, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk. Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).

Sophia Mamilli joined Novo Holdings in 2024. She is responsible for deal sourcing, execution, and portfolio management. Prior to joining Novo Holdings, Sophia was a Senior Associate on the healthcare team at General Atlantic, where she worked on private equity and growth equity investments. Prior to that, she was a private equity associate at Sun Capital Partners. Sophia began her career in the investment banking division of Morgan Stanley. Sophia holds a BA in Public Policy from Duke University and an MBA from Harvard Business School.

Sofie joined Novo Holdings A/S in July 2025 as Programme Director in the Strategy Office, where she is part of the Program and Projects team. Prior to joining Novo Holdings, Sofie held various roles at ISS A/S focused on M&A, strategy execution, and transformation. Before her time at ISS, she spent 10 years in M&A advisory at PwC and KPMG, working in both Copenhagen and London. Sofie holds an MSc in Finance and Strategic Management from Copenhagen Business School.

Sophia is a Vice President at Novo Holdings A/S in the Planetary Health Investments team. She has worked across the full investment lifecycle since joining the firm in October 2022, with investment experience spanning early-stage venture and late-stage buyout transactions. She also serves on the Boards of Directors of several portfolio companies. Prior to joining Novo Holdings, Sophia was Scientific Project Manager at the bio-industrial start-up Again Bio, where she was responsible for advancing R&D activities and coordinating a large carbon capture scale-up project. Earlier in her career, she focused on translating academic science into innovation and co-founded a sustainability initiative. Sophia holds a PhD in Metabolic Engineering from the Technical University of Denmark. Her academic work was carried out in collaboration with leading international research institutes and industry partners, including Novozymes, the Joint BioEnergy Institute, Lawrence Berkeley National Lab, UNSW Sydney, the University of Oxford, and the Technical University of Darmstadt.

Lesya Kulchenko is a technology managing director who joined Hercules in 2012. Her prior work includes Nourish, Hopewell Ventures, Raiffeisen credit in Ukraine and Rockwell Automation. She studied computer engineering at Marquette.

Sofie joined Novo Holdings A/S in February 2024 as an Associate in Principal Investments. She participates in deal sourcing and execution as well as in managing the existing portfolio. Prior to joining Novo Holdings A/S, Sofie worked as an Investment Banking Analyst at Goldman Sachs in London, focusing on buy-side and sell-side M&A advisory within the Consumer / Retail industry. Sofie holds a B.S. in Business Administration with a major in Finance from Georgetown University.

Sofie joined Novo Holdings in April 2023 as a Consultant in People & Organisation. She participates in rolling out strategic people-related projects such as transforming the people strategy into concrete talent initiatives and implementing people agenda activities in the organization. Prior to joining Novo Holdings, Sofie held a position as a Consultant in the Human Capital team at Deloitte, where she specialized in humanizing organizational transformations in the areas of change management, culture transformations, and behavioral change. Sofie holds a MSc in Strategic Market Creation from Copenhagen Business School

Simon joined Novo Holdings in September 2022 as an Associate in Novo Holdings China. Prior to joining Novo Holdings, Simon worked as an investment banking Associate at China International Capital Corporation, focusing on Greater China healthcare transactions. Before that, Simon worked as an investment banking analyst at Bank of America Merrill Lynch based out of Hong Kong. Simon graduated from Indiana University Bloomington Kelley School of Business with a Bachelor degree in Finance.

Cristy Barnes is a life-sciences managing director at Hercules. Her previous career includes healthcare investing at Lighthouse Capital and work at Highland Capital and Robertson Stephens. She studied psychology at UCLA.

Sihao joined Novo Holdings in September 2025 as an Associate in Novo Holdings China. Prior to joining Novo Holdings, Sihao worked as an Investment Associate at Hopu Investment, focusing on Greater China investments. Before that, Sihao worked as an investment banking analyst at UBS based out of Hong Kong. Sihao holds a Bachelor of Economics from Shanghai Jiao Tong University, and a Master of Finance from Shanghai Advanced Institute of Finance.

Simon Burr joined Venture Investments in 2022 as Associate, and is based in our London office. Simon is joined from a boutique life science consultancy specialising in competitive intelligence support, market analysis and commercial opportunity assessments. Previously, he worked within financial services at Gerson Lehrman Group providing diligence assistance to investor-clients across pharma, biotech and medtech sectors. Simon holds a PhD and MRes from King’s College London, and a first degree in Pharmacology, which included a year-long placement at AstraZeneca, from the University of Bath.

Skander Tahar Mulder joined Novo Holdings in 2026 as Lead AI & Software Engineer in the Data & Analytics team, where he supports the continued development of the Halo platform across sourcing, due diligence, and portfolio management. Prior to joining Novo Holdings, Skander worked at Novo Nordisk, where he focused on developing and implementing advanced data and AI solutions to support clinical and regulatory processes. He holds a PhD from UMC Groningen in bioinformatics and completed postdoctoral research at TU Delft, focusing on innovative data-driven approaches in healthcare.

John Eggbeer is a technology managing director based in Washington, DC. He joined Hercules in October2011 following work at MMV Financial and Comerica technology lending. He studied business at Richmond.

Sean joined Novo Holdings in May 2022 as Partner and Head of China. He has 10 years of healthcare investment experience.  Prior to Novo Holdings, Sean was employed as a Principal at Advent International, leading healthcare investing in China. Prior to Advent International, he worked at Warburg Pincus, where he spent five years focusing on investment in healthcare primarily in China and other key Asia markets.  Sean started his investing career at CITIC Capital, a control focused private equity firm in China.  Before investing, Sean worked in the investment banking division at UBS. Sean holds an dual BA in English Literature and Economics from Beijing Foreign Studies University.

Serena Chew joined Novo Holdings Asia in June 2023 as Head of P&O Asia. Prior to joining Novo Holdings, Serena was a Vice President for Organisation & People from Temasek International Pte Ltd and has previously worked for Korn Ferry International. Serena holds a Bachelor of Applied Science in Biotechnology from the National University of Singapore and has a Master in Biomedical Engineering from the Nanyang Technological University of Singapore.

Scott joined Venture Investments (US) Inc. in San Francisco, California in 2012. Previously, he was a board member of Aerocrine AB. From 2009-2012, Scott was part of Novo A/S’ Growth Equity team. Prior to joining Novo A/S he was a Managing Director at JP Morgan in San Francisco, heading the firm’s West Coast biopharmaceuticals effort. Previous to that, Scott led Piper Jaffray’s US biopharmaceuticals investment banking practice and was a member of the Health Care Group at Montgomery Securities. During his tenure as an investment banker, Scott originated and executed numerous transactions. Scott holds an MBA from UCLA’s Anderson Graduate School of Management and a BS from Colorado State University.

Sebastian Percy Teglskov is listed by Novo Holdings as Specialist in Finance & Operations. Further biography is not published on the reviewed profile.

Roy Y. Liu is a Hercules co-founder and managing director in technology. His earlier work includes GrandBanks Capital, VantagePoint, Imperial Bank and IBM research and development. He has an engineering and MBA background from Michigan and a communications patent.

Roman Camarda joined Venture Investments in 2022 as Senior Associate. Previous to that, Roman was a Vice President at Aquilo Capital Management where he focused on publicly traded biotech companies. Prior to Aquilo, Roman was Lead Translational Scientist at the Buck Institute where he worked with the business development office to create and incubate biotech start-ups. Roman holds a PhD in Biomedical Sciences from University of California, San Francisco, and a BS in Biochemistry and BFA in Photomedia from University of Washington.

Sandra joined Novo Holdings in August 2023 as an Operations Specialist in the People & Organisation department. Before joining Novo Holdings, Sandra was employed at The Danish Cancer Society as an HR Partner & Operations Specialist. Prior to this, Sandra worked for more than a decade at the University of Copenhagen in different roles such as HR Partner, Mobility Expert and Operations Specialist. Sandra holds an MA in International Business Communication from Aarhus University.

Sara joined Novo Holdings Asia in July 2025 as an Administrative Assistant. Sara previously worked at Goldman Sachs Singapore, where she held roles as an Executive Assistant and Analyst within the Human Capital Management team. Prior to Goldman Sachs, she was a Graduate Recruitment Coordinator at Shell. Sara holds a Bachelor of Business from the Royal Melbourne Institute of Technology (RMIT).

Sarah joined Novo Holdings in April 2026 as Senior P&O Partner in the People & Organisation team. Sarah’s role will be two-fold; she will act as Senior P&O Partner providing leadership sparring, driving strategic workforce planning and other topics linked to the people agenda. In addition, she will also act as a Learnings & Development Partner with responsibility for our peer group trainings, Novo Academy, and leadership programme. Prior to joining Novo Holdings, Sarah worked at Novo Nordisk since 2010 where she has worked across the entire value chain in various roles as specialist, HR leader, and HR Business Partner. Latest, Sarah has been Senior HR Business Partner for NN Enterprise IT, also responsible for developing talent and driving leadership programmes. Previously, Sarah headed up the Talent Acquisition team for NN Europe and had several other roles in International Operations and Global P&O. Sarah holds a MSc in Human Resource Management from Copenhagen Business School.

Lake McGuire is a managing director in Hercules’ life-sciences group. He previously spent a decade at Comerica working on venture-financing structures. He studied construction at Michigan State and completed a finance MBA at Michigan.

Non-executive director, Firmenich SA (current) Chief Executive Officer, Lonza Group (2012- Apr 2019) Executive Vice President, Cognis (2002-2011)

Robert Tichio joined Novo Holdings in 2026 as Senior Partner and Co-Head of US Planetary Health Investments. Robert is focused on investing in companies and platforms that harness technologies w ith clear environmental benefits to the industries in which they operate. Robert has 25 years of experience in the energy, infrastructure and industrials investment markets. Prior to joining Novo Holdings, Robert was Chief Executive Officer of Fortescue Capital, the decarbonization and sustainable infrastructure investment platform of global technology, energy and metals group Fortescue Limited. He also served as Senior Advisor to Novo Holdings’ Planetary Health Investments team. Previously, he was Partner and Managing Director at Riverstone Holdings, the energy and infrastructure private equity firm. He began his career at Goldman Sachs and J.P. Morgan. Robert received an MBA from Harvard Business School and a BA from Dartmouth College.

Rohit joined Novo Holdings Asia in December 2025 as an Associate. Prior to joining Novo Holdings, Rohit was an Investment Banking Associate with Moelis, where he worked on a range of transactions across the healthcare and consumer sectors. He has also previously worked with JP Morgan as an Investment Banking Analyst. He brings over five years of experience, with strong exposure to deal execution, sector research and financial analysis. He holds an MBA from the Indian Institute of Technology (IIT) Bombay and a Bachelor’s degree in Mechanical Engineering from the National Institute of Technology (NIT) Kurukshetra.

Mike Dutra is a senior managing director and senior investment officer in life sciences. He joined Hercules in June2014 after Goldman Sachs operations and DePuy Synthes quality work. He studied industrial engineering at Northeastern.

Rachel Weathered joined Novo Holdings in 2025 as an Associate on the Venture Investments team, based in Boston. Previously, Rachel was an Investment Analyst on the Global Equities team at UBS Asset Management, where she performed fundamental research on public biotech and life sciences companies to inform portfolio investments. Rachel holds a PhD in Molecular Engineering from the University of Chicago, with a focus in immunoengineering. She also holds a BS in Biomedical Engineering from Northwestern University.

Randi joined Novo Holdings in March 2021 as accountant. Her main responsibilities are bookkeeping and payments to vendors. Prior to joining Novo Holdings Randi was employed by ISS World Services as accounting specialist for more than 7 years, and prior to this Randi spent more than 6 year in Nomeco as  accountant and financial controller. Randi holds first part of Business Administration (HD).

Philip joined Novo Holdings A/S in January 2025 as Digital Architect to align business processes and strategy with digital solutions to ensure Novo Holdings reaches its ambitions for digital transformation. Prior to joining Novo Holdings A/S, Philip worked as Lead Solution Architect at VML MAP with responsibility for architecting and implementing marketing automation solutions and products. Philip holds a BSc, MSc, and PhD in Enterprise Systems from Copenhagen Business School.

Rafal Rybak joined Novo Holdings in March 2026 as Executive Assistant in Planetary Health, where he supports the Planetary Health Partners. Prior to joining Novo Holdings, Rafal worked as Executive Assistant at McKinsey & Company and Boston Consulting Group. Most recently, he served as Project Manager at Novo Nordisk. Rafal holds a Bachelor’s degree in Finance & International Business and a Master’s degree in Investment and Real Estate.

Thomas Harris is a senior managing director in Hercules’ technology group. His earlier career includes SVB syndications, technology investment banking at Bank of America and TD Securities. He studied finance at NYU and completed an MBA at Columbia.

Chairman of the Board, Biomason Board member warfair and Global Bio Fund Former President and CEO of Novozymes A/S

Peter joined Novo Holdings in February 2026 as a Risk Specialist, where he focuses on developing overarching risk management for Novo Holdings’ investments. Prior to joining Novo Holdings, Peter gained experience in public equity markets through Equity Research at SEB. He has also worked as a Data Engineering Consultant at Initiate, followed by a position in Quantitative Trading at Alipes Capital. Peter holds an MSc in Finance and Strategic Management from Copenhagen Business School

Peter Lytje is listed by Novo Holdings as Head of Risk & Compliance in Finance & Operations. Further biography is not published on the reviewed profile.

About Philippe Houssiau Belgian citizen Board positions Philippe has extensive board experience and currently serves on the boards of medneo, RAM Infotechnology, and Corilus. Career 2022 – Executive Chairman, medneo 2021 – Non-Executive Director, RAM Infotechnology 2020 –  Chairman of the Board, Corilus 2021 – 2023 Non-Executive Director, Mach7 Technologies 2021 – 2022 Non-Executive Chairman, Althea 2020 – 2021 Interim Chief Executive Officer, MAK-SYSTEM International Group 2019 – 2020 Chairman of the Board, Corepoint Health 2018 – 2020 Chairman of the Board, Rhapsody 2017 – 2020 Operating Partner, HgCapital 2015 – 2018 Chairman, 4ways 2013 – 2017 Vice President, General Manager Healthcare, DXC Technology 2010 – 2012 Group Chief Executive Officer, Alliance Medical Ltd 2009 – 2011 Chief Executive Officer, Telegentis NV 2002 – 2007 President, Healthcare Division, Agfa Gavaert Healthcare 1997 – 2002 Partner/Senior Partner, PwC 1994 – 1997 Director HR Europe, Raychem (now TE Connectivity) Education Philippe holds a degree in Chemical Engineering/Biotech and a BSc in Pharmaceutical Sciences, both from Vrije Universiteit Brussel.

Catherine Jhung originates technology and sustainability investments as a senior managing director. Her previous work includes Cleantech Group, edo Interactive and Equilar. She holds a Berkeley MBA and studied at UC Davis.

Jamey Thompson is currently Partner and Portfolio Manager, Sands Capital Horizons in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2025. Published career chronology (historical appointments): University of Virginia (2013 - Present) Charlottesville, VA | Department of Systems and Information Engineering Faculty Jocassee Quantitative, LLC (2021 - 2025) New York, NY and Charlottesville, VA | Managing Member Blackstone (2015 - 2020) New York, NY | Managing Director Citadel (2012 - 2013) Chicago, IL | Head of Quantitative Credit and Co-Head Global Credit Citadel (2008 - 2012) Chicago, IL | Senior Portfolio Manager King Street Capital Management, LLC (2005 - 2008) New York, NY | Trader. Education: Princeton University (2006) PhD | Operations Research and Financial Engineering Princeton University (2005) MA | Operations Research and Financial Engineering University of Virginia (2000) BS | Systems Engineering.

Joseph R. Andrasko is currently Chief Executive Officer and Chief Investment Officer, Sands Capital Horizons in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2025. Published career chronology (historical appointments): Fry’s Path Capital (2019 - 2025) Charlottesville, VA | Managing Partner UVA Darden School of Business (2015 - Present) Charlottesville, VA | Professor of Practice Murray Enterprises (2011 - 2019) Charlottesville, VA | Director of Investments Deloitte Consulting (2006 - 2008) Boston, MA | Analyst. Education: University of Virginia (2011) MBA | Darden School of Business Bowdoin College (2004) BA | Economics and Spanish.

Michele E. Wong is currently Legal Operations Associate in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2026. Published career chronology (historical appointments): StartYourRecovery (2025 - 2026) Alexandria, VA | Communications Consultant Reingold Inc (2024 - 2025) Alexandria, VA | Communications Specialist Institute of International Education (2023 - 2024) Washington, D.C. | Communications & Project Coordinator OST, Inc. (2019 - 2022) McLean, VA | Payroll Clerk Ashburn Eyecare Associates (2018 - 2019) Ashburn, VA | Receptionist. Education: George Mason University (2025) Paralegal Certificate American University (2022) BA | Journalism.

Morgan (Flagg) Fleites is currently Chief of Staff and Director, Client Advisory, Sands Capital Horizons in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2025. Published career chronology (historical appointments): Fry’s Path Capital (2021 - 2025) Charlottesville, VA | Senior Investment Associate Cambridge Associates (2016 - 2021) New York, NY | Senior Investment Associate. Education: Gettysburg College (2016) BA | Economics.

Naji Zien Alabdin is currently Cybersecurity and Software Engineer in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2023. Published career chronology (historical appointments): Sands Capital (2023 - 2025) Arlington, VA | Associate Software and Cybersecurity Support Engineer. Education: George Mason University (2023) BS | Cybersecurity Engineering.

Spencer M. Wheeler, Jr. is currently Partner and Portfolio Manager, Sands Capital Horizons in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2025. Published career chronology (historical appointments): Guardian Point Capital (2012 - 2025) Charlottesville, VA | Partner The Fiduciary Group (2010 - 2012) Savannah, GA | Director of Research Cotton Hall Asset Management (2007 - 2008) New York, NY | Junior Analyst. Education: University of Virginia (2007) BS | McIntire School of Commerce.

Member of the Novo Holdings Board since 2025. Member of the Novo Holdings Audit Committee. Narv Narvekar was born in 1962 in Washington D.C. and is a US national. Narv has a long and distinguished career leading investment organizations. Since 2017, he has served as CEO of Harvard Management Company (“HMC”). At HMC, he oversaw its successful restructuring and turnaround. Today he oversees the endowment and its portfolio, working closely with partners and colleagues.  Previously, he was CEO of Columbia University Investment Management Company for close to 15 years, running Columbia’s endowment. Prior, he was a Managing Director in the University of Pennsylvania Office of Investments. He began his career at JP Morgan where he worked for almost 15 years. Narv brings a long-term strategy and investment perspective from mission-driven organizations. Other Board Positions and Management Duties:   Advisory Board of McKinsey Investment Office “MIO” Advisory Board of ExB Group Advisory Board of Valence8

Ola joined Novo Holdings in April 2025 as a Senior Associate in Capital Investments. He is responsible for analyzing direct investment opportunities in the credit markets and managing partnerships with external managers. Prior to joining Novo Holdings, Ola spent four years at Nordea in the Leveraged Finance team, focusing on leveraged buyouts and the financing of private equity transactions. He holds an MSc in Applied Economics and Finance from Copenhagen Business School and a BSc in Business Administration from the University of Tromsø.

Paloma joined Novo Holdings Asia in September 2022. Prior to Novo Holdings, Paloma worked with JP Morgan’s Healthcare Banking team in Hong Kong. Before this, she was an Investment Banking Associate with China Renaissance and Bank of America Merrill Lynch. Paloma holds a Bachelor of Business Administration from Fudan University, and a Master of Business of Business Administration from MIT Sloan School of Management.

Paul Ewing-Chow joined Novo Holdings Asia in April 2024 as Head of Corporate Affairs Asia. Prior to joining Novo Holdings, Paul was Managing Director of Public Relations, Branding and Communications at CBC Group, a healthcare-dedicated investment firm. He has also served at Temasek International as Director of Public Affairs and was previously with Standard Chartered Bank in various roles at the bank’s Singapore and Dubai offices. Paul holds a Bachelor of Communications from the Edith Cowan University in Australia.

Steve Kuo leads Hercules’ technology investment group. His earlier career includes product management at silicon-photonics company Lightcross and investment work at Comdisco Ventures.

Julien Maquet is a financial analyst in the Q4 2024 WE Life Sciences roster, joined August 2024. Founded and sold a small company and studied biomedical sciences and biomedical data management, with programming, statistics and database skills. The dated public roster does not by itself establish a new employment start day or uninterrupted tenure through October 2026.

Akriti Shrestha is currently Business Analyst in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2019. Published career chronology (historical appointments): Sands Capital Management (2022 - 2025)Arlington, VA | Business and Data Associate Sands Capital Management (2019 - 2021)Arlington, VA | Technology Coordinator Breakout Capital Finance, LLC (2017 - 2019)McLean, VA | Executive Assistant to the EVP and General Counsel, EVP and CTO, EVP and CFO Euro Stone Craft (2013 - 2017)Herndon, VA | Assistant Manager NetSec Meds, Inc. (2012 - 2013)Ashburn, VA | Administrative Assistant. Education: Strayer University (2017)BBA | Finance Northern Virginia Community College (2015)AS | Computer Science.

Arthur Thomas IV is currently Sr. Full Stack Developer in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2019. Published career chronology (historical appointments): Sands Capital (2019 - 2025) Arlington, VA | Full Stack Developer University of Maryland, the Graduate School (2017 - 2019) College Park, MD | Systems Analyst. Education: University of Maryland College Park (2018) Bachelors | Government & Politics.

Avery L. Schober is currently Finance Manager in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2017. Published career chronology (historical appointments): Sands Capital (2024 - 2025) Arlington, VA | Sr. Financial Analyst Sands Capital (2022 - 2023) Arlington, VA | Financial Analyst Sands Capital (2017 – 2021) Arlington, VA | Jr. Financial Analyst. Education: Sewanee - The University of the South (2017) BA | Economics and Mathematics.

Gina Toussaint is currently Sr. Accountant in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2007. Published career chronology (historical appointments): Sands Capital (2012 - 2016) Arlington, VA | Staff Accountant Sands Capital (2007 - 2011) Arlington, VA | Accounting Assistant Sandy Spring Bank (2007) Olney, MD | Assistant VP for Vendor and Purchasing Cedars Medical Center (2005 - 2007) Miami, FL | Assistant Director for Ethics and Compliance. Education: Indiana University - Bloomington (2005) MS | Public Finance Administration.

Katie Tillotson is currently Corporate Accountant in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2025. Published career chronology (historical appointments): Northrop Grumman (2020 - 2025) Falls Church, VA | Senior Principal Financial Analyst Ernst & Young (2018 - 2020) Boston, MA | Audit Staff Cambridge Associates (2014 - 2017) Arlington, VA | Investment Operations Analyst. Education: University of North Carolina at Chapel Hill (2018) MA | Accounting University of Pittsburgh (2014) BS/BA | Economics and French.

Kristin N. Sizemore is currently Head of Human Resources in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2010. Published career chronology (historical appointments): Sands Capital (2010 - 2015) Arlington, VA | Director, Human Resources Folio Investing (2007 - 2010) McLean, VA | Director of Human Resources Information Management Consultants, Inc. (2000 - 2007) Reston, VA | Human Resources Supervisor. Education: The George Washington University (2005) MS | Organizational Management George Mason University (1998) BA | Sociology and English.

Laura J. Stewart is currently Director, Office and Events Planning in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2007. Published career chronology (historical appointments): Sands Capital (2020 - 2022) Arlington, VA | Sr. Manager, Office and Events Planning Sands Capital (2012 - 2019) Arlington, VA | Office Manager Sands Capital (2007 - 2011) Arlington, VA | Administrative Assistant Hurd I/T (2006 - 2007) McLean, VA | Executive Assistant Mica (2003 - 2006) Fairfax, VA | Title/Settlement Officer. Education: University of North Carolina at Chapel Hill (2003) BA | Journalism and Mass Communication.

Matthew Steele is currently Director, Applied AI Solutions in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2020. Published career chronology (historical appointments): Sands Capital (2022 - 2024) Arlington, VA | Data Analytics and Support Analyst Sands Capital (2020 - 2021) Arlington, VA | Data Analytics and Support Associate Thomson Reuters Special Services (2019 - 2020) McLean, VA | Data Engineer RiskSpan (2019 - 2019) Arlington, VA | Sr. Analyst RiskSpan (2018 - 2018) Arlington, VA | Analyst RiskSpan (2016 - 2017) Arlington, VA | Associate Analyst Mount St. Mary’s University (2015 - 2016) Emmitsburg, MD | Data Analyst. Education: Mount St. Mary’s University (2015) BS | Psychology.

Nigel Govett is Chief Financial Officer of Novo Holdings A/S, a position he has held since March 2022. In addition, Nigel is a member of the Board of Directors and Chair of the Audit Committee of NNIT A/S. From 2020 to 2022, Nigel was the Chief Financial Officer of Oman Infrastructure Investment Management. From 2014 to 2020, Nigel was Chief Financial Officer of the Sovereign Wealth Fund of Oman. Prior to this, Nigel held Director positions in EQT Fund Management Limited and EQT Partners UK, 2010-2014, and in Close Brothers including the role as Chief Operating Officer and Head of Fund Management (2007-2009). Nigel was a member of the Board of Directors of Outward Bound Oman from 2017-2022, and a member of the Board of Directors of Zain Group from 2017-2020. Nigel is Chair of the Board of Directors of Ejendomsselskabet Novo Holdings Komplementar ApS and Ejendomsselskabet Novo Holdings P/S, and Member of the Board of Directors of Novo Holdings US, Inc., as well as non-executive Chair of Tanjun 1 GP Limited in Guernsey (UK). Nigel is a UK national. He is admitted as a Fellow of the Association of Chartered Certified Accountants (ACCA) and holds a BA (Hons) Historical Studies from University of Sunderland and participated in the Global Board Education Programme with IMD in Lausanne.

Nine Cat Kejser is listed by Novo Holdings as Executive Assistant in Strategy and People. Further biography is not published on the reviewed profile.

Nis joined Novo Holdings A/S in 2016 and is Principal in the Planetary Health Investments team. Nis participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings, Nis was a Consultant with the Boston Consulting Group in their Copenhagen office. During his time with BCG, Nis worked primarily with Corporate Development and Strategy. Nis holds a MSc in Finance and Accounting and a BSc in International Business from Copenhagen Business School.

R. Bryan Jadot leads Hercules’ life-sciences investment group. He joined in 2005 following work at Silicon Valley Bank, BNP and the US Treasury. He studied economics and government at California State University, Sacramento.

Adam Rosenbaum is currently Sr. Data Governance Analyst in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2021. Published career chronology (historical appointments): Sands Capital (2021 - 2025) Arlington, VA | Data Governance Analyst Biotechnology Innovation Organization (2019 - 2021) Washington, D.C. | Manager, Analytics Akamai (2018 - 2019) Reston, VA | Engagement Manager Council for Advancement and Support of Education (2006 - 2018) Washington, D.C. | Director, Information Systems and Architecture Council for Opportunity in Education (2004 - 2005) Washington, D.C. | Assistant Director, Technology Education Democracy Data & Communications (2000 - 2004) Alexandria, VA | Database Administrator & Operations Specialist Montgomery County Public Schools (1995 -. Education: University Maryland Global Campus (2001) MS | Information Resource Management University of Colorado (1990) BA | Political Science.

Avery A.K.L. Salisbury is currently Director of Compliance in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2022. Published career chronology (historical appointments): ACA Global (2021 - 2022) Washington, D.C. | Senior Principal Consultant ExodusPoint Capital Management, LP ( 2020 – 2021) New York, NY | Deputy Chief Compliance Officer – Regulatory Compliance Gresham Investment Management, LLC (2015 - 2020) New York, NY | Managing Director & Chief Compliance Officer Eton Park Capital Management, LP (2013 – 2015) New York, NY | Senior Compliance Associate Anchorage Capital Group, LLC (2011 - 2013) New York, NY | Compliance Associate ACA Compliance Group (2010 - 2011) New York, NY |. Education: Trinity College (CT) (2007) BA | Political Science.

Elma Rahman is currently Sr. Technology Coordinator in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2021. Published career chronology (historical appointments): Sands Capital (2021 - 2025) Arlington, VA | Technology Coordinator Gensler (2017 - 2021) Washington, D.C. | Studio Coordinator Gensler (2011 - 2017) Washington, D.C. | Executive Assistant Infectious Diseases Society of America (2007 - 2010) Arlington, VA | Administrative Coordinator Legg Mason Wood Walker, Inc. (2001 - 2006) Alexandria, VA | Client Services Representative. Education: George Mason University (2001) BA | English.

Eric C. Perlish is currently Managing Director, Head of Trading and Risk Analytics in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2011. Published career chronology (historical appointments): Sands Capital (2020 - 2024) Arlington, VA | Global Head of Trading Sands Capital (2015 - 2019) Arlington, VA | Head of Global Trading Sands Capital (2011 - 2014) Arlington, VA | Sr. Trader Ironbound Capital (2004 - 2010) Princeton, NJ | Head Trader Cisco Systems (2004) Malvern, PA | Project Analyst Merrill Lynch Investment Managers (1998 - 2003) Plainsboro, NJ | Assistant Vice President. Education: Rider University (1997) BBA | Actuarial Science and Finance.

Patricia D. Rodriguez is currently Reconciliation Administration Supervisor in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 1999. Published career chronology (historical appointments): Sands Capital (2004 - 2008)Arlington, VA | Sr. Reconciliation Administrator Sands Capital (2003 - 2004)Arlington, VA | Trade Settlement Specialist Sands Capital (1999 - 2003)Arlington, VA | Account Administrator.

Susan H. Saunders is currently Director of People Operations and Development in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2015. Published career chronology (historical appointments): Sands Capital (2024 - 2025) Arlington, VA | Sr. Manager, HR Business Partner Sands Capital (2022 - 2023) Arlington, VA | Manager, HR Business Partner Sands Capital (2015 - 2021) Arlington, VA | Sr. HR Business Partner GridPoint, Inc. (2008 - 2015) Arlington, VA | Human Resources Generalist Family Advocacy Services (2007 - 2008) Newington, VA | Clinical Therapist For Children's Sake (2005 - 2007) Chantilly, VA | Case Manager. Education: Virginia Commonwealth University (2005) MSW | Clinical Concentration University of Colorado, Boulder (1999) BA | Psychology.

Timothy Richter is currently Director, Fund and Investment Operations in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2022. Published career chronology (historical appointments): Sands Capital (2022 - 2025) Arlington, VA | Sr. Manager, Fund and Investment Operations Barings, LLC (2021 - 2022) Charlotte, NC | Director – Head of US and UK High Yield Portfolio Services Barings, LLC (2018 - 2020) Charlotte, NC | Manager – Global Client and Portfolio Services Barings, LLC (2015 - 2018) Charlotte, NC | Associate Director – Global Client and Portfolio Services Babson Capital Management (2013 - 2015) Charlotte, NC | Analyst – Global Client and Portfolio Services BMO Financial Group (2010 -. Education: University of Wisconsin (2010) BA | Economics.

Nicolaj joined Novo Holdings A/S in March 2024 as a Data Engineer. He contributes to the enhancement of the data platform and elevating advanced analytics capabilities. Prior to being at Novo Holdings A/S, Nicolaj worked at Ørsted as a part of the Market Data Team in the Department of Financial Risk Management and Market Analytics, focusing on data enhancement and analytics for FX and commodity markets. Nicolaj holds a BSc in Mathematics and Technology and an honors MSc in Mathematical Modeling and Computation from the Technical University of Denmark, complemented by a semester at Cornell University.

Vedavyas Munugoor is currently Investment Systems Support Engineer in Sands Capital’s published firmwide directory. The biography records joining or rejoining: 2025. Published career chronology (historical appointments): RainFocus (2023 – 2025) Arlington, VA | Data Integration Engineer Fidelity Investments (2020 – 2023) Boston, MA | Investment Systems Engineer. Education: Wentworth Institute of Technology (2021) BS | Computer Science.

Nicole Jepsen joined Novo Holdings A/S as Personal Assistant in Capital Investments in September 2020. Prior to joining Novo Holdings A/S, Nicole was employed as Executive Assistant and Head of HR at the commercial property advisor Nordicals København A/S- Savills for 7 years. Other previous employments include positions as Operations Manager at KfW IPEX-Bank in London and EA at Verint Systems in Germany. Nicole holds a BA degree in Modern Languages and Cultural Mediation from the University of Southern Denmark.

Nav joined Novo Holdings Asia in August 2021. He focusses on deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in China, India, and Southeast Asia. Prior to joining Novo Holdings Asia, Nav was a Director in Quadria Capital, a mid-market private equity firm focusing on healthcare investments in India and South East Asia. Before joining Quadria Capital, Nav was the Managing Director at Fosun, where he worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Nav started his investment career with Merrill Lynch in Hong Kong and moved to UBS Global Asset Management in Singapore before joining Fosun. Nav holds an MBA from Indian Institute of Management (IIM), Ahmedabad, in India and Bachelor of Technology from Indian institute of Technology (IIT), Kharagpur in India.

Nick joined Novo Holdings in May 2026 as a Senior Investment Operations Specialist in Finance & Operations. Prior to joining Novo Holdings, Nick worked 11 years in the financial sector. First five years in Jyske Bank as an Investment Operations Specialist, then one year at Investering & Tryghed as an Investment Controller and latest five years at Aleta as an Investment Operations Manager. Nick holds a Graduate Diploma in Business Administration (Finance).

Jasmine Saadati oversees corporate development, institutional fundraising and limited-partner relationships for the Hercules private-credit platform and Hercules Adviser. She previously spent more than ten years at SVB Capital across credit, product and investor relations.

Gery Lefebvre is an investment manager in the Q4 2024 WE Life Sciences roster since 2014, with management and finance experience including treasury and working-capital responsibilities at GSK Biologicals. Holds HEC-ULiège business-administration and taxation master’s degrees. The dated public roster does not by itself establish a new employment start day or uninterrupted tenure through October 2026.

Nana joined Novo Holdings in November 2022 as Senior P&O Partner in the People & Organisation team. She supports and collaborates closely with Leaders and teams on topics linked to the people agenda to ensure we uphold an inclusive and performance-driven workplace, and supports the development journeys of our people professionally and personally. Prior to joining Novo Holdings, Nana worked at McKinsey & Company in Copenhagen for 15 years in the People Development team, overseeing people matters and was responsible for the development and staffing of consultants, as well as being advisor and sparring partner for the Leadership team. Nana holds a BSc in Business Administration and Psychology and an MSc in Strategy, Organisation and Leadership from Copenhagen Business School.

Board Director at Cancer Treatment Centers of America Formerly President, CEO and Board Director for PDI, and CMO at Novartis US